Page last updated: 2024-11-07

prednisone and Metastase

prednisone has been researched along with Metastase in 429 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

ExcerptRelevanceReference
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo."9.30Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019)
"Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel."9.22Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016)
"In patients with mCRPC progressing after docetaxel chemotherapy, abiraterone acetate and prednisone yielded clinically meaningful improvements in patient-reported fatigue compared with prednisone alone."9.17Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. ( Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN, 2013)
"When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity."9.08A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E, 1997)
"Sixty-seven patients with advanced breast cancer were prospectively entered into a Phase II trial of cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously (i."9.07A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. ( Bishop, JF; Dipell, JF; Jeal, P; Laidlaw, CR; Olver, IN; Rischin, D; Zimet, A, 1992)
"The prospective controlled phase III clinical trial compared the therapeutic value of the cis-platinum - adriamycin - cyclophosphamide combination (CAP) and that of the combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisolone (CMFVP) in untreated metastatic breast cancer."9.05CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. ( Cervek, J; Kolarić, K; Roth, A; Vukas, D, 1984)
"To evaluate the association of the use of concomitant BRIs with overall survival (OS) and time to first SRE among patients with mCRPC and bone metastases receiving abiraterone acetate with prednisone as first-line therapy."8.02Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. ( Alimohamed, NS; Bengala, C; Bryce, AH; Cigliola, A; Crivelli, F; Francini, E; Francini, G; Garcia-Foncillas, J; Gonzalez-Velez, M; Harshman, LC; Heng, DYC; Higano, CS; Lee-Ying, R; Montagnani, F; Moreno-Candilejo, I; Nuzzo, PV; Petrioli, R; Rosellini, P; Rubio-Perez, J; Shaw, GK; Sweeney, CJ; Zhang, L, 2021)
"Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7."7.67Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. ( Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989)
"Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine."7.66Clinical trial of nafoxidine in advanced breast cancer. ( De Jager, RL; Krakoff, IH; Steinbaum, FL, 1978)
"Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle."6.75A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010)
"Concerning bone metastases there was no difference between the two schedules in response rate, nor in the median remission duration (CAP 11, FAC 10 months)."6.66Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. ( Kolarić, K; Potrebica, V; Vukas, D, 1989)
"The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo."5.30Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. ( Boegemann, M; Heidenreich, A; Higano, C; Kakehi, Y; Karyakin, O; Kimura, G; Krissel, H; Matsubara, N; Matveev, V; Miller, K; Nahas, WC; Ng, QS; Nolè, F; Parker, C; Piulats, JM; Rosenbaum, E; Saad, F; Shen, J; Smith, M; Teufel, M; Tombal, B; Wagner, V; Zhang, A; Zucca, LE, 2019)
"Men with mHNPC having ≥2 of 3 high-risk factors (Gleason score ≥8, ≥3 bone lesions or measurable visceral metastases) randomly received abiraterone acetate 1000-mg+ prednisone 5-mg+ADT (AAP group) or ADT+Placebos (Placebo group)."5.27Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. ( Enjo, K; Fizazi, K; Fukasawa, S; Kawaguchi, K; Matsubara, N; Noguchi, H; Suzuki, H; Todd, M; Tran, N, 2018)
"Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel."5.22Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016)
"The present multicenter phase II trial evaluated the safety and efficacy of pegylated liposomal doxorubicin (PLD) instead of conventional doxorubicin in standard R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisone) therapy for elderly patients with diffuse large B-cell lymphoma."5.20Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. ( Astrow, AB; Durand, JB; Ewer, MS; Fanale, M; Fayad, LE; Fisch, MJ; Fowler, N; Hagemeister, FB; Huang, X; Kwak, LW; Lenihan, DJ; McLaughlin, P; Neelapu, SS; Oki, Y; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Wang, M; Younes, A, 2015)
"In patients with mCRPC progressing after docetaxel chemotherapy, abiraterone acetate and prednisone yielded clinically meaningful improvements in patient-reported fatigue compared with prednisone alone."5.17Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. ( Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN, 2013)
"The association of cycle 1 neutropenia with overall survival (OS) was examined post hoc in a randomized phase II trial of 221 men with mCRPC who received docetaxel-prednisone combined with placebo or AT-101 (bcl-2 inhibitor); weekly blood cell counts were performed during the first cycle."5.16Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. ( Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA, 2012)
"To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed."5.13The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008)
"When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity."5.08A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E, 1997)
"One hundred ninety-five women (141 eligible) whose disease was in CR or in CR except for bone metastases following six cycles (6 months) of doxorubicin-containing induction treatment were randomized to receive cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, and halotestin [CMF(P)TH] or observation."5.08Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. ( Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D, 1998)
"Sixty-seven patients with advanced breast cancer were prospectively entered into a Phase II trial of cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously (i."5.07A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. ( Bishop, JF; Dipell, JF; Jeal, P; Laidlaw, CR; Olver, IN; Rischin, D; Zimet, A, 1992)
" Our earlier study in breast cancer showed that second-line CAP (cyclophosphamide, adriamycin, cis-platinum) treatment was not cross-resistant to the CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) regimen and produced a 51% response rate."5.06cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study. ( Kolarić, K; Tomek, R, 1990)
"A randomized trial was performed to determine relative efficacy and toxicity of two first-line combination chemotherapy regimens in women with metastatic breast cancer: CFP (cyclophosphamide, 5-fluorouracil, prednisone) and CMFP (cyclophosphamide, 5-fluorouracil, methotrexate, prednisone)."5.06Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. ( Cullinan, SA; Ebbert, LP; Ingle, JN; Krook, JE; Mailliard, JA; Marschke, RF; Pfeifle, DM; Schaid, DJ; Votava, HJ; Windschitl, HE, 1989)
"Ninety-seven eligible and evaluable women with metastatic breast cancer were placed on a prospective clinical protocol to evaluate the use of continuous cyclic therapy with dibromodulcitol, doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH) v DAVTH alternating with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP); and the use of pretreatment and serial carcinoembryonic antigen (CEA) levels in these patients."5.06Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. ( Chang, AY; Davis, TE; Falkson, G; Falkson, HC; Loprinzi, CL; Rasmussen, P; Tormey, DC, 1986)
"The prospective controlled phase III clinical trial compared the therapeutic value of the cis-platinum - adriamycin - cyclophosphamide combination (CAP) and that of the combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisolone (CMFVP) in untreated metastatic breast cancer."5.05CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. ( Cervek, J; Kolarić, K; Roth, A; Vukas, D, 1984)
"Seventy patients with advanced metastatic breast cancer were treated with an oral drug regime of prednisone, cytomel, cytoxan, and methotrexate."5.05Treatment of breast cancer with oral four-drug chemotherapy. ( Foley, JF; Kessinger, MA; Lemon, HM, 1980)
"In 1977 we reported our results of an ongoing randomized clinical trial evaluating early or delayed adjuvant chemotherapy utilizing 5-flourouracil, cytoxan and prednisone in premenopausal patients with recurrent or advanced breast cancer."5.05An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Green, SJ; Hahn, RG; Ingle, JN; Lee, RA, 1982)
"One hundred fifty-five eligible women with metastatic breast cancer were randomly allocated to receive monthly cycles of either CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone) or CAF (cyclophosphamide, doxorubicin, 5-fluorouracil), and 12 patients were studied to evaluate the effects of additional Corynebacterium parvum immunotherapy."5.05Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. ( Cummings, FJ; Gelman, R; Horton, J, 1985)
"We treated randomly 75 premenopausal patients with advanced breast cancer with combination chemotherapy (5-fluorouracil, cyclophosphamide and prednisone), either as an early adjunct to oophorectomy or as a delayed treatment upon appearance of progressive metastatic disease after operation."5.04An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Hahn, RG; Lee, RA; O'Connell, MJ, 1977)
"A randomized clinical trial, involving approximately 100 patients, that compared two combination therapy regimens (5 FU, methotrexate, vincristine, cyclophosphamide with and without prednisone) in advanced breast cancer showed a significantly higher rate of response for the 5-drug therapy group (62."5.04Combination chemotherapy in breast cancer: a randomized study of 4 versus 5 drugs. ( Cornell, GN; Klotz, J; Madden, RE; Minton, JP; Ramirez, G; Strawitz, JG; Wilson, WL, 1975)
"When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 ((223)Ra; for men with predominantly bone metastases)."4.90Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. ( Basch, E; Bennett, CL; Carducci, M; Chen, RC; Dusetzina, SB; Frame, JN; Garrels, K; Hotte, S; Kattan, MW; Loblaw, DA; Oliver, TK; Raghavan, D; Rumble, RB; Saad, F; Taplin, ME; Virgo, KS; Walker-Dilks, C; Williams, J; Winquist, E; Wootton, T, 2014)
"To evaluate the association of the use of concomitant BRIs with overall survival (OS) and time to first SRE among patients with mCRPC and bone metastases receiving abiraterone acetate with prednisone as first-line therapy."4.02Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. ( Alimohamed, NS; Bengala, C; Bryce, AH; Cigliola, A; Crivelli, F; Francini, E; Francini, G; Garcia-Foncillas, J; Gonzalez-Velez, M; Harshman, LC; Heng, DYC; Higano, CS; Lee-Ying, R; Montagnani, F; Moreno-Candilejo, I; Nuzzo, PV; Petrioli, R; Rosellini, P; Rubio-Perez, J; Shaw, GK; Sweeney, CJ; Zhang, L, 2021)
"Clinical records of patients with pretreated advanced breast cancer and who were treated with the Metronomic-Cooper-type regimen consisting of weekly fixed doses of NPLD (30 mg IV) plus 5-Fluorouracil (5-FU) (500 mg IV) plus vincristine (0."3.79Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. ( Ciruelos, E; Cortés-Funes, H; Dorta, M; Ghanem, I; Manneh, R; Manso, L; Mendiola, C; Sepúlveda, J; Valdiviezo, N; Vega, E, 2013)
"Five responses (lung metastases, three; lymph node metastases, two) were observed in 23 patients with metastatic renal cell carcinoma who received recombinant interferon-alpha-2A (IFN) 18 X 10(6) U in three intramuscular doses each week combined with oral prednisone (10 to 20 mg daily)."3.68Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study. ( Fosså, SD; Gunderson, R; Moe, B, 1990)
"21 patients with metastatic breast cancer, refractory to conventional agents, were treated with a combination of BCNU, vincristine, mitomycin-C and prednisone given every 4 weeks."3.67Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study. ( Anderson, P; DiBella, NJ; Fink, K; Garfield, D; Murphy, J; Speer, J, 1984)
"Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7."3.67Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. ( Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989)
"One hundred and ten patients with stage IV breast cancer were treated with five-drug chemotherapy consisting of prednisone, cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine."3.66Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. ( Manni, A; Pearson, OH; Trujillo, JE, 1980)
"The five-drug combination of fluorouracil imidazole carboxamide dimethyl triazeno, vincristine, bis-chloroethyl nitrosourea, and prednisone (FIVB + P) was given to 120 women with metastatic breast cancer."3.66A five-drug combination in the treatment of metastatic breast cancer. ( Falkson, G; Falkson, HC, 1981)
"Combination chemotherapy consisting of cyclophosphamide, vincristine, prednisone, and procarbazine (COPP) was administered to 5 patients with invasive lymphoepithelial thymoma."3.66Combination chemotherapy in invasive thymoma role of COPP. ( Evans, WK; Feld, R; Phillips, MJ; Simpson, WJ; Thompson, DM, 1980)
"Three patients with Hodgkin disease, eight with non-Hodgkin lymphoma, and one with chronic lymphocytic leukemia refractory to conventional combination chemotherapy were treated for remission induction with a new kinetically designed four-drug combination consisting of bleomycin, vincristine, adriamycin, and prednisone and given the acronym "BOAP."3.66A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients. ( Braine, HG; Coltman, CA; Kerr, RO; Rossof, AH, 1978)
"Forty-nine postmenopausal patients with advanced breast cancer were treated with a nonsteroidal antiestrogen, Nafoxidine."3.66Clinical trial of nafoxidine in advanced breast cancer. ( De Jager, RL; Krakoff, IH; Steinbaum, FL, 1978)
"Cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone were administered for 165, 28-day cycles to 33 patients with metastatic breast cancer."3.65Leucovorin in combination chemotherapy of breast cancer. ( Corder, MP; Flannery, EP; Herbst, KD; Justice, GR; Sheets, RF; Stone, WH, 1977)
"Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2 intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle."3.65Combination chemotherapy for advanced breast cancer: response and effect on survival. ( Canellos, GP; Chabner, BA; DeVita, VT; Gold, GL; Schein, PS; Young, RC, 1976)
"Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle."3.65Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974)
" Grade 3/4 adverse events were reported in 24 (68."2.94Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. ( Fizazi, K; Fukasawa, S; Hashine, K; Kitani, S; Matsubara, N; Mundle, S; Ohtake, N; Shibayama, K; Shin, T; Suzuki, H; Tran, N, 2020)
"The cumulative incidences of visceral metastases were calculated by the Kaplan-Meier method and compared using log-rank testing."2.90Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. ( Antonarakis, ES; Carducci, MA; Denmeade, SR; Qiu, F; Teply, BA, 2019)
"Apatorsen treated patients received a median of 19 infusions."2.87A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. ( Chi, KN; Ellard, SL; Gingerich, JR; Gleave, ME; Hotte, SJ; Joshua, AM; Yu, EY, 2018)
" The major adverse effects were bone marrow suppression, reduction of fibrinogen level, liver dysfunction, and digestive tract toxicities."2.87PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. ( Deng, L; Gao, Y; Ke, X; Lin, N; Liu, W; Ping, L; Ren, H; Song, Y; Su, L; Tu, M; Wang, X; Xie, Y; Ying, Z; Zhang, C; Zhang, W; Zheng, W; Zhu, J, 2018)
" Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392)."2.82A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. ( Chae, YS; Eom, HS; Hong, J; Hong, JY; Kim, HJ; Kim, JS; Kim, SJ; Kim, WS; Lee, GW; Lee, S; Lee, SM; Oh, SY; Park, E; Park, J; Ryoo, HM; Suh, C; Won, JH; Yang, DH; Yoon, DH, 2016)
"Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC)."2.82Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. ( Bergman, A; Bögemann, M; Cruciani, G; De Bono, J; De Giorgi, U; De Wit, R; Feyerabend, S; Fizazi, K; Hessel, C; Hoelzer, W; Houédé, N; Hussain, S; Krainer, M; Lam, E; Le Moulec, S; Mainwaring, P; Miller, K; Oudard, S; Polikoff, J; Ramies, D; Saad, F; Smith, M; Stenzl, A; Sternberg, C; Thiery-Vuillemin, A; Weitzman, A, 2016)
"This was a phase I/II trial to determine the safety and efficacy of alisertib when given in combination with abiraterone plus prednisone (AP)."2.82A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. ( Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z, 2016)
" Specific adverse events with abiraterone-prednisone were similar between the age subgroups."2.80Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. ( Carles, J; Griffin, TW; Kheoh, T; Li, J; Molina, A; Mulders, PF; Rathkopf, DE; Ryan, CJ; Smith, MR; Van Poppel, H, 2015)
"Visceral disease, non-nodal soft-tissue metastases predominantly involving the lung and liver, is a negative prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC)."2.79Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. ( de Bono, JS; Fizazi, K; Flaig, TW; Goodman, OB; Kheoh, T; Li, J; Molina, A; Mulders, PF; Scher, HI; Suttmann, H, 2014)
"Treatment with abiraterone acetate and prednisone was well tolerated by patients who were treated for >2 yr."2.79Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). ( Beer, TM; Carles, J; de Bono, JS; de Souza, P; Efstathiou, E; Fizazi, K; Flaig, TW; Fradet, Y; Griffin, TW; Hainsworth, JD; Higano, CS; Kheoh, T; Logothetis, CJ; Mainwaring, P; Molina, A; Mulders, PF; North, S; Park, YC; Rathkopf, DE; Ryan, CJ; Saad, F; Scher, HI; Shore, ND; Small, EJ; Smith, MR; Taplin, ME; Todd, MB; Van Poppel, H; Yu, EY; Yu, MK, 2014)
"Also, the Follicular Lymphoma International Prognostic Index (FLIPI) score increased in 18% (26 of 142) and decreased in 6% (9 of 142) of patients."2.78The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. ( Arcaini, L; Biasoli, I; Boccomini, C; Carella, AM; D'Arco, AM; Di Raimondo, F; Federico, M; Ferreri, AJ; Gaidano, G; Gallamini, A; Luminari, S; Mastronardi, S; Merli, F; Musto, P; Rusconi, C; Santoro, A; Spina, M; Versari, A; Zinzani, PL, 2013)
" Intetumumab serum concentrations increased with repeated dosing and did not reach steady-state."2.78A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c ( Bogdanova, N; Dawkins, F; de Boer, CJ; Dirix, L; Heidenreich, A; Rawal, SK; Schrijvers, D; Stenzl, A; Szkarlat, K; Wang, G; Welslau, M, 2013)
"This phase 1/2 study assessed sunitinib combined with docetaxel (Taxotere) and prednisone in chemotherapy-naive metastatic, castration-resistant prostate cancer (mCRPC) patients."2.77Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. ( Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ, 2012)
"We performed a dose-escalation study to investigate the safety of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer (mCRPC)."2.77Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. ( Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S, 2012)
"These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim."2.76Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. ( Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011)
" Most treatment-emergent adverse events (TEAEs) occurred in the 10-mg/kg intetumumab group."2.76A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. ( Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J, 2011)
"Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle."2.75A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010)
"Ultimately, patients with metastatic prostate cancer progress on androgen ablation therapy."2.72Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer. ( Borden, LS; Clark, PE; Hall, MC; Harmon, M; Lovato, J; M Mohler, R; Stindt, D; Torti, FM, 2006)
" Abiraterone acetate in combination with prednisone was the first approved hormone therapy demonstrating survival benefit, and represents, to date, an alternative, or a second-line treatment after taxane-based chemotherapy, in addition to androgen-deprivation therapy, in hormone sensitive, and metastatic castration-resistant prostate cancer."2.66Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. ( Manceau, C; Mourey, L; Ploussard, G; Pouessel, D, 2020)
"Concerning bone metastases there was no difference between the two schedules in response rate, nor in the median remission duration (CAP 11, FAC 10 months)."2.66Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. ( Kolarić, K; Potrebica, V; Vukas, D, 1989)
"Body weight was the only risk factor found to be associated with statistically significant differences in survival."2.65Body weight and prognosis in breast cancer. ( Boyd, NF; Campbell, JE; Germanson, T; Meakin, JW; Sutherland, DJ; Thomson, DB, 1981)
"Since in the treatment of advanced breast cancer chemotherapy and the various hormonal manipulations seem recently to have reached a plateau of effectiveness when used alone, it is widely assumed that the combination of both treatment modalities could improve therapeutic results."2.65[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer]. ( Alberto, P; Beer, M; Brunner, KW; Cavalli, F; Jungi, WF; Martz, G; Mermillod, B; Obrecht, JP, 1982)
"Patients with advanced breast carcinoma and no prior chemotherapy were prospectively evaluated to assess the induction capabilities of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), Adriamycin and vincristine (AV), and CMF plus prednisone (CMFP)."2.65Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. ( Band, PR; DeWys, W; Gelman, R; Perlia, C; Rice, MA; Rosenthal, SN; Sears, M; Tormey, DC, 1982)
"However, since most patients with breast cancer present with local or regional disease but go on to die of disseminated cancer, major improvements in survival are most likely to occur by treating this neoplasm as a systemic disease through cobmining effective local therapy with systemic treatments."2.64Chemotherapy of disseminated breast cancer. Current status and prospects. ( Band, P; Bauer, M; Carbone, PP; Tormey, D, 1977)
"The volume of metastases, as defined in the CHAARTED study for instance, could be an interesting predictive factor."2.55Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. ( Albiges, L; Audenet, F; Barthelemy, P; Beuzeboc, P; Fléchon, A; Gravis, G; Irani, J; Linassier, C; Oudard, S; Rebillard, X; Richaud, P; Rouprêt, M; Rozet, F; Thiery Vuillemin, A; Timsit, MO; Vincendeau, S, 2017)
"One patient experienced disease progression."2.50[Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review]. ( Ma, H; Wan, B; Wang, JY; Wu, PJ; Zhu, G, 2014)
"If metastatic prostate cancer progresses despite androgen suppression, the two main options in 2012 are either: palliative treatment with corticosteroids and external beam radiation therapy or radioisotope infusion; or docetaxel followed by abiraterone, which slightly prolongs survival but at a cost of sometimes serious adverse effects."2.49Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief. ( , 2013)
"A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere, Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC)."2.44A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. ( Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Perard, R; Riemsma, R; Trowman, R, 2007)
"In hormone-sensitive metastatic prostate cancer, androgen deprivation represents the first-line treatment."2.44Management of metastatic prostate cancer: the crucial role of geriatric assessment. ( Chaladaj, A; Droz, JP, 2008)
"Visceral metastasis (VM) and a higher number of bone metastasis generally define high volume/risk in patients with metastatic castration-sensitive prostate cancer (mCSPC)."1.91Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer. ( Choueiri, TK; Gillessen, S; McKay, RR; Ürün, Y; Yekedüz, E, 2023)
"Treatment with abiraterone acetate or enzalutamide is one of the approved approaches in men with metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting."1.56Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study. ( Eterović, D; Omrčen, T; Vrdoljak, E, 2020)
"Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure."1.51Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. ( Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F, 2019)
"Fatigue was commonly linked to poor HRQoL and responses indicated that significantly fewer patients in the AAP group reported feeling usually tired or fatigued in the last week compared to the ENZ group (33% vs."1.51Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer. ( Artenie, C; Dearden, L; Gater, A; Grant, L; Jackson, C; Mills, A; Shalet, N, 2019)
" Pharmacokinetic evaluation was performed at two consecutive visits at least 4 weeks apart."1.51Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. ( Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP, 2019)
"Differentiated thyroid cancer is the most common endocrine malignancy with concomitant hematological malignancy in 7%."1.48Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report. ( Bochev, P; Cirocchi, R; Hristoskova, R; Mutafchiyski, VM; Philipov, A; Popivanov, GI; Tabakov, M, 2018)
"Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL)."1.46A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one. ( Go, SI; Kang, JH; Kang, MH; Kim, HG; Kim, HR; Lee, GW; Park, MJ; Song, HN, 2017)
"Abiraterone is a well-tolerated and effective treatment modality for patients affected with metastatic castration-resistant prostate cancer."1.46Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study. ( Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A, 2017)
" All patients experienced at least one adverse event during induction, most commonly infusion-related reactions (58%), the majority of which were grade 1/2."1.46Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. ( Díaz, MG; Dreyling, M; Dyer, MJ; Grigg, A; Knapp, A; Lei, G; Marlton, P; Rule, S; Wassner-Fritsch, E, 2017)
"Eplerenone is a nonsteroidal mineralocorticoid antagonist demonstrated to abrogate mineralocorticoid excess."1.46Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. ( Agarwal, N; Alex, A; Bailey, E; Batten, J; Boucher, K; Gaston, D; Gill, D; Gupta, S; Hahn, A; Stenehjem, D, 2017)
"Prednisone use was associated with a reduced risk of progression on docetaxel in the propensity score-weighted multivariable Cox model (P=0."1.43The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. ( Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA, 2016)
"Cabazitaxel/prednisone has been shown to prolong survival versus mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or after docetaxel."1.40Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. ( Bracarda, S; Climent, MA; Fossa, S; Heidenreich, A; Hitier, S; Mason, M; Ozen, H; Papandreou, C; Sengelov, L; Van Oort, I, 2014)
"Periodontitis has been observed infrequently in bevacizumab-containing chemotherapy in clinical practice."1.39A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. ( Akiyoshi, K; Hamaguchi, T; Hosokawa, A; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Ogawa, K; Shimada, Y; Sugiyama, T; Ueno, T; Yamada, Y, 2013)
"Abiraterone was also associated with cardiac arrhythmias (7."1.38Abiraterone. After prostate cancer treatment failure: 4-month survival advantage. ( , 2012)
"Considerations were Devic's disease versus metastases."1.36Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness. ( Molina, RM; Navarra, SV; Soldevilla, HF, 2010)
"The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high."1.31Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000)
"Because thymoma is a chemosensitive tumor and frequently recurs in patients with Stage II or greater disease, chemotherapy carries a potential survival benefit and should be incorporated into the multimodality approach to prolong disease-free survival."1.29Thymoma. A retrospective study of 87 cases. ( Cox, JD; Hong, WK; Komaki, R; Lee, JS; Park, HS; Pollack, A; Putnam, JB; Shin, DM, 1994)
"Neoadjuvant chemotherapy in Hodgkin's disease has improved survival time and tolerance to irradiation, allowing a lowering of the total doses used and the volumes irradiated."1.28[Radiotherapy with neoadjuvant chemotherapy]. ( Alapetite, C; Baillet, F; Dessard-Diana, B; Housset, M; Jacquillat, C; Michel-Langlet, P, 1989)
"Chemotherapy results in metastatic breast cancer reached a plateau: Remission rate and duration are nearly equivalent for several regimens but not equitoxic."1.27[Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma]. ( Hartlapp, JH; Illiger, HJ; Peiss, J; Vaupel, HA, 1983)
"Nevertheless, because breast cancer is one of the most responsive of the solid tumors to cytotoxic drugs, appropriately chosen chemotherapy can relieve symptoms and prolong survival."1.27Chemotherapy of advanced breast cancer. A general survey. ( Loeb, V; Lyss, AP, 1984)
"Distant metastases and chemotherapy in malignant thymoma are reviewed."1.27Malignant thymoma with distant metastases: a case report and review of the literature. ( Ichino, Y; Ishikawa, T; Obuchi, M; Suko, K, 1983)
"Twenty-three patients with metastatic breast carcinoma were induced with a complex systemic therapy regimen in an attempt to ascertain if a complete remission rate greater than 50% could be obtained with intensive drug exposure."1.27Short term high density systemic therapy for metastatic breast cancer. ( Carbone, PP; Davis, TE; Kline, JC; Love, RR; Palta, M; Tormey, DC, 1985)
" Reduction of the steroid dosage was followed by regression of the tumor."1.26Kaposi's sarcoma complicating corticosteroid therapy for temporal arteritis. ( Fam, AG; Leung, F; Osoba, D, 1981)
" While earlier results suggested that adjuvant chemotherapy is especially effective in premenopausal women, newer studies and analyses indicate that appropriate dosage and consistent administration of chemotherapy are of decisive importance."1.26[Results of, and indications for adjuvant chemotherapy in breast cancer]. ( Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L, 1981)
"Breast cancer is the most common cause of cancer death in women in this country."1.26Modern approaches to the treatment of breast cancer. ( Knight, WA; McGuire, WL; Osborne, CK; Yochmowitz, MG, 1980)
" The development of interstitial pneumopathy after this low bleomycin dosage may have been favored by a previous thorax irradiation 22 years earler for round cell sarcoma."1.26[Interstial pneumopathy after low dose bleomycin therapy]. ( Frey, F; Marone, C; Zimmermann, A, 1977)
"Cases of disintegrating pulmonary metastases are presented."1.26[Confluent pulmonary deposits from carcinoma of the breast under cytostatic therapy (author's transl)]. ( Blechschmidt, CM; Schermuly, W, 1976)
"A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems."1.26[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976)
"Four patients suffering spinal cord compression resulting from epidural metastases were treated with adrenocorticosteroid hormones."1.26"Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases. ( Cvitkovic, E; Howieson, J; Posner, JB, 1977)
"The meningeal metastasis was treated by surgery and irradiation with orbital penetration; the lymph nodes were irradiated, and COPP polychemotherapy was given to treat the rest of the metastatic localizations."1.26[Extraskeletal manifestations of unusual localization in a case of myeloma (author's transl)]. ( Caballero, O; Martínez, J; Marty, ML; Mayans, J; Sanz, MA, 1979)
"91 women with metastatic breast cancer, who received prior CTX-5FU or CTX-5FU-PRD, were treated in 3 consecutive clinical trials with either CTX-5FU-PRD-MTX-VCR, MTX-VCR, or MTX-VCR-PRD in order to elucidate whether the effectiveness of 5 drugs was due only to the newly added drugs (MTX-VCR +/- PRD) or whether the previously used drugs (CTX-5FU) were necessary as potentiating agents."1.26Potentiating role of previously administered agents in the combination chemotherapy of breast cancer. ( Nemoto, T; Rosner, D; Snyderman, M, 1979)
"Soft tissue metastases may be more responsive than bony lesions."1.26Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate. ( Bergreen, PW; Buell, GV; Saiers, JH; Saiki, JH, 1978)
"Seventy-two women with metastatic breast cancer were treated with multiple-agent chemotherapy."1.26Combination chemotherapy in the treatment of advanced breast cancer. ( Dao, TL; Nemoto, T; Rosner, D, 1976)
"Osteoblastic bony metastases were observed in a case of medulloblastoma three years after surgery and radiation treatment."1.26Generalized osteoblastic bony metastases from medulloblastoma. ( DeLand, FH; Ho, EP; Lieber, A; Maruyama, Y, 1976)
"Therapy for acute lymphocytic leukemia (ALL) has been less successful in adults than in children."1.26Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone. ( George, JN; Scavino, HF; Sears, DA, 1976)
"Three cases of hepatocellular carcinoma are reported in young men who had been taking androgenic-anabolic steroids."1.25Androgen-induced hepatoma. ( Baird, PJ; Farrell, GC; Joshua, DE; Kronenberg, H; Perkins, KW; Uren, RF, 1975)
"Although breast cancer presents as localized disease and is treated with local modalities, i."1.25Chemotherapy in the treatment strategy of breast cancer. ( Carbone, PP, 1975)
"A patient had metastatic lymphosarcoma involving the right atrium and tricuspid valve in which functional tricuspid valve obstruction was relieved by chemotherapy."1.25Lymphosarcoma of the right atrium. Angiographic and hemodynamic documentation of response to chemotherapy. ( Garfein, OB, 1975)
" Dosage adjustments were often necessary during the initial phases of therapy."1.25A controlled study in the use of combined drug therapy for metastatic breast cancer. ( Alberto, P; Brunner, KW; Martz, G; Obrecht, P; Senn, HJ; Sonntag, RW, 1975)
"Seventeen patients with metastatic breast carcinoma were treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide and prednisone."1.25Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma. ( Blom, J; Stutz, FH; Tormey, DC, 1973)

Research

Studies (429)

TimeframeStudies, this research(%)All Research%
pre-1990250 (58.28)18.7374
1990's17 (3.96)18.2507
2000's21 (4.90)29.6817
2010's123 (28.67)24.3611
2020's18 (4.20)2.80

Authors

AuthorsStudies
Saad, F15
Efstathiou, E5
Attard, G2
Flaig, TW7
Franke, F1
Goodman, OB3
Oudard, S11
Steuber, T1
Suzuki, H3
Wu, D1
Yeruva, K1
De Porre, P7
Brookman-May, S1
Li, S2
Li, J9
Thomas, S1
Bevans, KB1
Mundle, SD2
McCarthy, SA1
Rathkopf, DE8
Yekedüz, E1
McKay, RR1
Gillessen, S1
Choueiri, TK1
Ürün, Y1
George, DJ7
Thiery-Vuillemin, A3
Poulsen, MH1
Lagneau, E1
Ploussard, G2
Birtle, A2
Dourthe, LM1
Beal-Ardisson, D1
Pintus, E1
Trepiakas, R1
Lefresne, F1
Lukac, M1
Van Sanden, S2
Pissart, G1
Reid, A1
Rouyer, M1
Joly, F2
Fizazi, K20
Tubach, F1
Jove, J1
Lacueille, C1
Lamarque, S1
Guiard, E1
Balestra, A1
Droz-Perroteau, C1
Fourrier-Reglat, A1
Moore, N1
Khalaf, DJ2
Annala, M1
Taavitsainen, S1
Finch, DL2
Oja, C2
Vergidis, J2
Zulfiqar, M2
Sunderland, K2
Azad, AA1
Kollmannsberger, CK3
Eigl, BJ2
Noonan, K1
Wadhwa, D1
Attwell, A1
Keith, B1
Ellard, SL3
Le, L1
Gleave, ME3
Wyatt, AW1
Chi, KN7
Feyerabend, S3
Perualila, NJ1
Diels, J1
Ito, T1
Matsubara, N4
Özgüroğlu, M1
Rodriguez-Antolin, A1
Fein, L1
Alekseev, BY1
Sulur, G1
Protheroe, A2
Mundle, S2
Tran, N6
Shin, T1
Fukasawa, S2
Hashine, K1
Kitani, S1
Ohtake, N1
Shibayama, K1
Carretero-González, A1
Lora, D1
Manneh, R2
Lorente, D3
Castellano, D4
de Velasco, G1
Du, M1
Tian, Y1
Tan, W2
Wang, L6
Kilari, D1
Huang, CC1
Kohli, M2
Shore, N1
Higano, CS7
Sternberg, CN5
Tombal, B3
Miller, K3
Kalinovsky, J1
Jiao, X1
Tangirala, K1
Sartor, O4
Omrčen, T1
Eterović, D1
Vrdoljak, E1
Manceau, C1
Mourey, L2
Pouessel, D1
Fang, WY1
Wang, PF1
Fan, YC1
Shih, HJ1
Madan, RA2
Karzai, FH1
Al Harthy, M1
Petrylak, DP4
Kim, JW1
Arlen, PM1
Rosner, I1
Theoret, MR1
Cordes, L1
Bilusic, M1
Peer, CJ1
Dawson, NA1
Couvillon, A1
Hankin, A1
Williams, M1
Chun, G1
Owens, H1
Marte, JL1
Lee, MJ1
Tomita, Y1
Yuno, A1
Trepel, JB1
Lee, S3
Steinberg, SM2
Gulley, JL2
Figg, WD4
Dahut, WL2
Boerrigter, E1
Benoist, GE1
van Oort, IM1
Verhaegh, GW1
van Hooij, O1
Groen, L1
Smit, F1
Oving, IM1
de Mol, P1
Smilde, TJ1
Somford, DM1
Mehra, N1
Schalken, JA1
van Erp, NP1
Ternov, KK1
Nolsøe, AB1
Bratt, O1
Fode, M1
Lindberg, H1
Kistorp, C1
Palapattu, G1
Klausen, TW1
Sønksen, J1
Østergren, PB1
Pelloux-Prayer, R1
Schiele, P1
Gravis, G2
Kleinclauss, F1
Crehange, G1
Hennequin, C1
Morgans, AK1
Geoffrois, L1
Limat, S1
Nerich, V1
Francini, E1
Montagnani, F1
Nuzzo, PV1
Gonzalez-Velez, M1
Alimohamed, NS1
Rosellini, P1
Moreno-Candilejo, I1
Cigliola, A1
Rubio-Perez, J1
Crivelli, F1
Shaw, GK1
Zhang, L1
Petrioli, R1
Bengala, C1
Francini, G1
Garcia-Foncillas, J1
Sweeney, CJ1
Bryce, AH2
Harshman, LC1
Lee-Ying, R1
Heng, DYC1
Xiong, X1
Qiu, S1
Yi, X1
Xu, H1
Liao, D1
Lei, H1
Bai, S1
Peng, G1
Ai, J1
Yang, L1
Mostaghel, EA1
Marck, BT1
Kolokythas, O1
Chew, F1
Yu, EY4
Schweizer, MT1
Cheng, HH1
Kantoff, PW2
Balk, SP1
Taplin, ME6
Sharifi, N1
Matsumoto, AM1
Nelson, PS1
Montgomery, RB1
Cicero, G2
DE Luca, R2
Dorangricchia, P1
Dieli, F2
Smith, MR6
Mulders, PFA2
de Bono, JS17
Small, EJ11
Shore, ND5
Kheoh, T14
Todd, MB4
Yu, MK4
Ryan, CJ12
Go, SI1
Park, MJ1
Song, HN1
Kim, HG1
Kang, MH1
Kang, JH1
Kim, HR1
Lee, GW2
Struss, WJ1
Black, PC1
Scott, LJ1
Blasi, L1
Pepe, A1
Pavone, C1
Simonato, A1
Yamauchi, T1
Kinoshita, K1
Imamura, S1
Kamiya, K1
Dehm, SM1
Hillman, DW1
Sicotte, H1
Gormley, M1
Bhargava, V1
Jimenez, R1
Xie, F1
Yin, P1
Qin, S1
Quevedo, F1
Costello, BA1
Pitot, HC1
Ho, T1
Ye, Z2
Li, Y1
Eiken, P1
Vedell, PT1
Barman, P1
McMenomy, BP1
Atwell, TD1
Carlson, RE1
Ellingson, M1
Eckloff, BW1
Qin, R1
Ou, F1
Hart, SN1
Huang, H1
Jen, J1
Wieben, ED1
Kalari, KR1
Weinshilboum, RM1
Climent, MÁ2
Pérez-Valderrama, B1
Mellado, B1
Fernández Parra, EM1
Fernández Calvo, O1
Ochoa de Olza, M1
Muinelo Romay, L1
Anido, U1
Domenech, M1
Hernando Polo, S1
Arranz Arija, JÁ1
Caballero, C1
Juan Fita, MJ1
Sun, Y1
Lee, SK1
Oo, TH1
Rojas-Hernandez, CM1
Stein, CA1
Levin, R1
Given, R1
Nemeth, P1
Bosch, B1
Chapas-Reed, J1
Dreicer, R2
Hotte, SJ1
Gingerich, JR1
Joshua, AM3
Hussain, M1
Daignault-Newton, S1
Twardowski, PW1
Albany, C1
Stein, MN1
Kunju, LP1
Siddiqui, J1
Wu, YM1
Robinson, D1
Lonigro, RJ1
Cao, X1
Tomlins, SA1
Mehra, R1
Cooney, KA1
Montgomery, B2
Antonarakis, ES4
Shevrin, DH2
Corn, PG1
Whang, YE1
Smith, DC2
Caram, MV1
Knudsen, KE1
Stadler, WM1
Feng, FY1
Chinnaiyan, AM1
Amber, KT1
Valdebran, M1
Lu, Y1
De Feraudy, S1
Linden, KG1
Popivanov, GI1
Bochev, P1
Hristoskova, R1
Mutafchiyski, VM1
Tabakov, M1
Philipov, A1
Cirocchi, R1
Elkon, JM1
Millett, RL1
Millado, KF1
Lin, J2
Hamilou, Z1
Baciarello, G1
Thakur, MK1
Heilbrun, L2
Dobson, K1
Boerner, J1
Stark, K1
Smith, D2
Heath, E2
Fontana, J1
Vaishampayan, U2
Yan, X1
Zhou, M1
Lou, Z1
Mu, Q1
Sheng, L1
Zhang, P1
Wang, Y2
Ouyang, G1
Poorthuis, MHF1
Vernooij, RWM1
van Moorselaar, RJA1
de Reijke, TM1
Olmos, D2
Mateo, J2
Dolling, D1
Bianchini, D3
Seed, G2
Flohr, P2
Crespo, M2
Figueiredo, I2
Miranda, S2
Scher, HI11
Terstappen, LWMM1
Arays, R1
Wang, P1
Su, YJ1
Wang, PN1
Chang, H1
Shih, LY1
Lin, TL1
Kuo, MC1
Chuang, WY1
Wu, JH1
Tang, TC1
Hung, YS1
Dunn, P1
Kao, HW1
Boiché, M1
Conart, JB1
Angioi-Duprez, K1
Fenioux, C1
Louvet, C1
Charton, E1
Rozet, F2
Ropert, S1
Prapotnich, D1
Barret, E1
Sanchez-Salas, R1
Mombet, A1
Cathala, N1
Joulia, ML1
Molitor, JL1
Henriques, J1
Bonnetain, F1
Cathelineau, X1
Bennamoun, M1
Zheng, W1
Gao, Y1
Ke, X1
Zhang, W1
Su, L1
Ren, H1
Lin, N1
Xie, Y1
Tu, M1
Liu, W1
Ping, L1
Ying, Z1
Zhang, C1
Deng, L1
Wang, X1
Song, Y1
Zhu, J1
Kawaguchi, K1
Noguchi, H1
Enjo, K1
Todd, M1
Dearden, L1
Shalet, N1
Artenie, C1
Mills, A1
Jackson, C1
Grant, L1
Gater, A1
Grochtdreis, T1
König, HH1
Dobruschkin, A1
von Amsberg, G1
Dams, J1
Hakenberg, OW1
Perez-Gracia, JL1
Demkow, T2
Ali, T1
Caffo, O1
Heidenreich, A5
Schultze-Seemann, W1
Sautois, B1
Pavlik, I1
Qin, A1
Novosiadly, RD1
Shahir, A1
Ilaria, R1
Nippgen, J1
Halabi, S3
Dutta, S1
Tangen, CM1
Rosenthal, M1
Thompson, IM1
Araujo, JC1
Logothetis, C2
Quinn, DI1
Morris, MJ3
Eisenberger, MA2
Tannock, IF5
Kelly, WK3
Hahn, AW1
Gill, DM1
Poole, A1
Nussenzveig, RH1
Wilson, S1
Farnham, JM1
Stephenson, RA1
Cannon-Albright, LA1
Maughan, BL1
Agarwal, N2
Ivanov, N1
Fan, L1
Yang, Y1
Chi, C1
Ma, X1
Wang, R1
Gong, Y1
Zheng, H1
Pan, J1
Zhu, Y2
Dong, B1
Xue, W1
Mehta-Shah, N1
Ito, K1
Bantilan, K1
Moskowitz, AJ1
Sauter, C1
Horwitz, SM1
Schöder, H1
Smith, M2
Parker, C1
Ng, QS1
Boegemann, M1
Matveev, V1
Piulats, JM2
Zucca, LE1
Karyakin, O1
Kimura, G1
Nahas, WC1
Nolè, F1
Rosenbaum, E1
Kakehi, Y1
Zhang, A1
Krissel, H1
Teufel, M1
Shen, J1
Wagner, V1
Higano, C2
Długosz-Danecka, M1
Szmit, S1
Ogórka, T1
Skotnicki, AB1
Jurczak, W1
Hansen, AR1
Templeton, A1
Chen, E1
Evans, A1
Knox, J1
Prawira, A1
Sridhar, SS2
Tan, S1
Vera-Badillo, F2
Wouters, BG1
Teply, BA2
Qiu, F1
Carducci, MA2
Denmeade, SR2
Arasaratnam, M1
Crumbaker, M1
Bhatnagar, A1
McKay, MJ1
Molloy, MP1
Gurney, H2
Mannuel, H1
Liu, G3
Lara, P1
Monk, JP1
Flaig, T1
Zurita, A1
Mack, P1
Stella, P1
Bolton, S1
Hussain, A1
Al-Janadi, A1
Silbiger, D1
Usman, M1
Ivy, SP1
Ricciuti, B1
Dahlberg, SE1
Adeni, A1
Sholl, LM1
Nishino, M1
Awad, MM1
Zhao, J1
Zhang, M1
Liu, J2
Liu, Z1
Shen, P1
Nie, L1
Guo, W1
Cai, D1
Armstrong, CM1
Sun, G1
Chen, J2
Zhu, S1
Dai, J1
Zhang, H1
Zhao, P1
Zhang, X1
Yin, X1
Zhu, X1
Ni, Y1
Chen, N1
Zeng, H1
Castellan, P1
Castellucci, R1
Marchioni, M1
De Nunzio, C1
Tema, G1
Primiceri, G1
Schips, L1
Cindolo, L1
Keating, GM1
Luminari, S1
Biasoli, I1
Arcaini, L1
Versari, A1
Rusconi, C1
Merli, F1
Spina, M1
Ferreri, AJ2
Zinzani, PL2
Gallamini, A1
Mastronardi, S1
Boccomini, C1
Gaidano, G1
D'Arco, AM1
Di Raimondo, F1
Carella, AM1
Santoro, A1
Musto, P1
Federico, M1
Chau, CH1
Gao, R1
Sissung, TM1
Spencer, S1
Beatson, M1
Aragon-Ching, J1
Harzstark, AL1
Rosenberg, JE1
Weinberg, VK2
Sharib, J1
Pagliaro, LC1
Beer, TM4
Molina, A12
Mulders, PF5
Suttmann, H2
Delva, R1
Sevin, E1
Bompas, E1
Vedrine, L1
Ravaud, A1
Eymard, JC2
Tubiana-Mathieu, N1
Linassier, C2
Houede, N3
Guillot, A1
Ringensen, F1
Cojocarasu, O1
Valenza, B1
Leconte, A1
Lheureux, S1
Clarisse, B1
Michaelson, MD1
Ou, YC1
Sengeløv, L1
Ostler, P1
Stenzl, A3
Daugaard, G1
Jones, R1
Laestadius, F1
Ullèn, A1
Bahl, A1
Gschwend, J1
Maurina, T1
Chow Maneval, E2
Wang, SL2
Lechuga, MJ1
Paolini, J1
Chen, I2
Leibowitz-Amit, R1
Templeton, AJ2
Omlin, A1
Pezaro, C1
Atenafu, EG1
Keizman, D1
Seah, JA1
Knox, JJ1
Bracarda, S2
Mason, M1
Ozen, H1
Sengelov, L1
Van Oort, I1
Papandreou, C1
Fossa, S1
Hitier, S1
MARTINEZDIAZ, J1
Pytlík, R1
Belada, D1
Kubáčková, K1
Vášová, I1
Kozák, T1
Pirnos, J1
Bolomská, I1
Matuška, M1
Přibylová, J1
Campr, V1
Burešová, L1
Sýkorová, A1
Berková, A1
Klener, P1
Trněný, M1
Broccoli, A1
Pellegrini, C1
Celli, M1
Argnani, L1
Agostinelli, C1
Pileri, S1
Logothetis, CJ5
de Souza, P3
Mainwaring, P5
Hainsworth, JD2
North, S5
Fradet, Y1
Van Poppel, H3
Carles, J3
Griffin, TW5
Park, YC1
Jung, SH1
Yang, DH2
Ahn, JS1
Kim, YK1
Kim, HJ3
Lee, JJ1
Bellmunt, J2
Loriot, Y2
Ok, CY1
Xu-Monette, ZY1
Tzankov, A1
Manyam, GC1
Li, L1
Visco, C1
Montes-Moreno, S1
Dybkær, K1
Chiu, A1
Orazi, A1
Zu, Y1
Bhagat, G1
Richards, KL1
Hsi, ED1
Choi, WW1
van Krieken, JH1
Huh, J1
Zhao, X1
Ponzoni, M1
Bertoni, F1
Farnen, JP1
Møller, MB1
Piris, MA1
Winter, JN1
Medeiros, LJ1
Young, KH1
Ma, H1
Zhu, G1
Wan, B1
Wu, PJ1
Wang, JY1
Geynisman, DM1
Szmulewitz, RZ1
Plimack, ER1
Singal, R1
Ramachandran, K1
Gordian, E1
Quintero, C1
Zhao, W1
Reis, IM1
Basch, E2
Loblaw, DA1
Oliver, TK1
Carducci, M1
Chen, RC1
Frame, JN1
Garrels, K1
Hotte, S2
Kattan, MW1
Raghavan, D1
Walker-Dilks, C1
Williams, J1
Winquist, E4
Bennett, CL1
Wootton, T1
Rumble, RB1
Dusetzina, SB1
Virgo, KS1
Auchus, RJ1
Nguyen, S1
Patel, JN1
Jiang, C1
Hertz, DL1
Mulkey, FA1
Owzar, K1
Ratain, MJ1
Friedman, PN1
Mahoney, JF1
Kelley, MJ1
McLeod, HL1
Oki, Y1
Ewer, MS1
Lenihan, DJ1
Fisch, MJ1
Hagemeister, FB1
Fanale, M1
Romaguera, J1
Pro, B1
Fowler, N1
Younes, A1
Astrow, AB1
Huang, X1
Kwak, LW1
Samaniego, F1
McLaughlin, P1
Neelapu, SS1
Wang, M1
Fayad, LE1
Durand, JB1
Rodriguez, MA1
Aggarwal, RR1
Lin, AM1
Alumkal, J1
Graff, JN1
Nordquist, LT1
Herrera, I1
Larson, SM1
Matheny, SL1
Naini, V1
Burzykowski, T1
Lance, RS1
Gardner, TA1
Karsh, LI1
Fong, L1
McCoy, C1
DeVries, T1
Sheikh, NA1
GuhaThakurta, D1
Chang, N1
Redfern, CH1
Oh, SY1
Kim, WS1
Kim, JS1
Chae, YS1
Eom, HS1
Ryoo, HM1
Kim, SJ1
Yoon, DH1
Won, JH1
Hong, J1
Park, J1
Lee, SM1
Hong, JY1
Park, E1
Suh, C1
Chang, K1
Kong, YY1
Dai, B2
Ye, DW2
Qu, YY1
Jia, ZW1
Li, GX1
Davis, ID1
Schrijvers, D3
Stöckle, M1
Ohlmann, CH1
Meisel, A1
von Felten, S1
Vogt, DR1
Liewen, H1
de Wit, R5
de Bono, J2
Stenner-Liewen, F1
Tagawa, ST2
Posadas, EM1
Bruce, J1
Lim, EA1
Peng, W1
Maul, S1
Smit, JW1
Gonzalez, MD1
Nanus, DM1
Luber, B1
Pilon, D1
Queener, M1
Lefebvre, P1
Ellis, LA1
Fleisher, M1
Danila, DC1
Baeten, K1
McCormack, R1
Terstappen, LW1
Sternberg, C1
Le Moulec, S1
De Giorgi, U1
Krainer, M1
Bergman, A1
Hoelzer, W1
Bögemann, M1
Cruciani, G1
Hussain, S1
Lam, E1
Polikoff, J1
Ramies, D1
Hessel, C1
Weitzman, A1
Audenet, F1
Irani, J1
Timsit, MO1
Barthelemy, P1
Beuzeboc, P1
Fléchon, A3
Rebillard, X1
Richaud, P1
Rouprêt, M1
Thiery Vuillemin, A1
Vincendeau, S1
Albiges, L1
Sonpavde, G3
Pond, GR3
Kwon, ED1
Tsao, CK1
Sfakianos, J1
Liaw, B1
Gimpel-Tetra, K1
Kemeny, M1
Bulone, L1
Shahin, M1
Oh, WK1
Galsky, MD3
Takeuchi, T1
Yamaguchi, M1
Kobayashi, K1
Miyazaki, K1
Tawara, I1
Imai, H1
Ono, R1
Nosaka, T1
Tanaka, K1
Katayama, N1
Grigg, A1
Dyer, MJ1
Díaz, MG1
Dreyling, M1
Rule, S1
Lei, G1
Knapp, A1
Wassner-Fritsch, E1
Marlton, P1
Gill, D1
Gaston, D1
Bailey, E1
Hahn, A1
Gupta, S1
Batten, J1
Alex, A1
Boucher, K1
Stenehjem, D1
Patel, SA1
Sama, AR1
Hoffman-Censits, JH1
Kennedy, B1
Kilpatrick, D1
Yang, H1
Mu, Z1
Leiby, B1
Lewis, N1
Cristofanilli, M1
Ruether, D1
Ernst, S1
Cheng, T2
Perrotte, P1
Karakiewicz, P1
Machiels, JP2
Mazzeo, F1
Clausse, M2
Filleul, B1
Marcelis, L1
Honhon, B1
D'Hondt, L2
Dopchie, C1
Verschaeve, V1
Duck, L2
Verhoeven, D1
Jousten, P1
Bonny, MA1
Moxhon, AM1
Kerger, J2
Witjes, JA1
Ferrero, JM1
Falcon, S1
Calabrò, F1
James, N1
Bodrogi, I1
Harper, P1
Wirth, M1
Berry, W1
Petrone, ME1
McKearn, TJ1
Noursalehi, M1
George, M1
Rozencweig, M1
Buch-Hansen, TZ1
Bentzen, L1
Hansen, S1
Hoeyer, M1
Jensen, NV1
Saxe, C1
Sengeloev, L1
Kummar, S1
Gutierrez, ME1
Gardner, ER1
Melillo, G1
Dancey, J1
Sausville, EA1
Conley, BA1
Murgo, AJ1
Doroshow, JH1
Armstrong, AJ4
Eisenberger, M2
Chu, FM1
Picus, J1
Fracasso, PM1
Lang, Z1
Foster, B1
Eton, DT1
Beaumont, J1
Victorson, D1
Cella, D1
Soldevilla, HF1
Molina, RM1
Navarra, SV1
El Halim Mohamed Abu Hamar, A1
Mansour, S1
El Shebiney, M1
El Bary, NM1
Sadaka, E1
Maria, A1
Chu, L1
Jones, RJ1
Staffurth, JN1
Harland, S1
Hutson, TE2
Patterson, H1
Saleh, M1
Scholz, M1
Zivi, A1
Chieffo, N1
Haqq, CM2
Buckman, R1
Eigl, B1
Chi, K1
Czaykowski, P1
Wood, L1
Pollak, M1
Berry, S1
Lattouf, JB1
Mukherjee, SD2
Gleave, M1
Zurita, AJ1
Wilding, G1
Kozloff, M1
Mathew, P1
Harmon, CS1
Beltran, H1
Berruti, A1
Pia, A1
Terzolo, M1
Voog, E1
Davis, NB1
Qi, M1
Bandekar, R1
Vermeulen, JT1
Cornfeld, M1
Hudes, GR1
Wood, BA2
Leopold, L2
Mardjuadi, F1
Medioni, J1
Canon, JL1
Musuamba, F1
Moxhon, A1
Shen, YJ1
Bian, XJ1
Xie, HY1
Zhang, HL1
Zhang, SL1
Yao, XD1
Berry, WR1
Ogawa, K1
Ueno, T1
Kato, K1
Nishitani, H1
Akiyoshi, K1
Iwasa, S1
Nakajima, TE1
Hamaguchi, T1
Yamada, Y1
Hosokawa, A1
Sugiyama, T1
Shimada, Y1
Tolcher, A1
Lee, P1
Rosen, PJ1
Papadopoulos, KP1
Patnaik, A1
Jiao, J1
Pankras, C1
Kaiser, B1
Bernard, A1
Acharya, M1
Rawal, SK1
Szkarlat, K1
Bogdanova, N1
Dirix, L1
Welslau, M1
Wang, G1
Dawkins, F1
de Boer, CJ1
Pal, SK1
Hao, Y1
Rothman, M1
Gagnon, DD1
Cleeland, C1
Ng, S1
Gerritsen, WR1
Pantuck, A1
Park, Y1
Griffin, T1
Manso, L1
Valdiviezo, N1
Sepúlveda, J1
Ciruelos, E1
Mendiola, C1
Ghanem, I1
Vega, E1
Dorta, M1
Cortés-Funes, H1
Kim, YB1
Chang, SK1
Yang, WI1
Hahn, JS1
Koom, WS1
Shim, SJ1
Park, W1
Lee, KK1
Suh, CO1
Kim, GE1
Mak, YK1
Chan, CH1
Li, CK1
Lee, MP1
Tsang, YW1
Weiss, RB1
Woolf, SH1
Demakos, E1
Holland, JF2
Berry, DA1
Falkson, G5
Cirrincione, CT1
Robbins, A1
Bothun, S1
Henderson, IC1
Norton, L1
Rago, RP1
Einstein, A1
Lush, R1
Ko, YJ1
Henner, WD1
Bubley, G1
Merica, EA1
Garg, V1
Ette, E1
Harding, MW1
Dalton, WS1
Foley, MR1
Moshfeghi, DM1
Wilson, MW1
Haik, BG1
Pappo, AS1
Hill, DA1
SCHOYER, NH1
SCHMIDT, E1
SCHMIDT, FW1
ADAMS, JE1
GARDNER, B2
GRAHAM, WP1
GORDAN, GS1
LOKEN, HF1
THOMAS, AN1
TEAL, JS1
SCHOEN, D1
FEINE, U1
MCGOVERN, EL1
PERRIN, WE1
WILLAMO, HH2
CONKLIN, EF1
ALBANESE, AA1
LORENZE, EJ1
ORTO, LA1
SMULLYAN, I1
NISSEN-MEYER, R2
KARNOFSKY, DA1
NELSON, RS1
DEELIZALDE, R1
SJOERDSMA, A2
MELMON, KL2
GREENSPAN, EM1
LAMBERG, BA1
PELKONEN, R1
FRICK, MH1
RUDERMAN, NB1
HALL, TC1
MARTIN, DC1
RUBINI, M1
ROSEN, VJ1
MANNHEIMER, IH1
STRATFORD, EC1
TANAKA, KR1
Reichenberg, JS1
Sagar, S1
Davis, MD1
Borden, LS1
Clark, PE1
Lovato, J1
Hall, MC1
Stindt, D1
Harmon, M1
M Mohler, R1
Torti, FM1
Collins, R1
Fenwick, E1
Trowman, R1
Perard, R1
Norman, G1
Light, K1
Palmer, S1
Riemsma, R1
Escofet, X1
Khan, AZ1
Mazarani, W1
Woods, WG1
Garrett-Mayer, ES1
Yang, YC1
Ennishi, D1
Yokoyama, M1
Mishima, Y1
Watanabe, C1
Terui, Y1
Takahashi, S1
Takeuchi, K1
Ikeda, K1
Tanimoto, M1
Hatake, K1
Droz, JP1
Chaladaj, A1
Thuret, R1
Massard, C1
Gross-Goupil, M1
Escudier, B1
Di Palma, M1
Bossi, A1
de Crevoisier, R1
Chauchereau, A1
Blix, S1
Jacobsen, CD1
Moure, JM2
Ezrin, C1
Briant, TD1
Firestone, G1
Rosen, F1
Muirhead, W1
Manni, A2
Trujillo, JE1
Pearson, OH2
Moser, K1
Pohl, A1
Pezner, RD1
Bertrand, M1
Cecchi, GR1
Paladugu, RR1
Kendregan, BA1
Illiger, HJ1
Peiss, J1
Vaupel, HA1
Hartlapp, JH1
Kolarić, K3
Roth, A1
Vukas, D2
Cervek, J1
Hryniuk, W1
Bush, H1
Sledge, GW2
DiBella, NJ1
Garfield, D1
Fink, K1
Anderson, P1
Speer, J1
Murphy, J1
Lyss, AP1
Loeb, V1
Goodnough, LT1
Saito, H1
Jones, PK1
Schumm, F1
Brinkmann, A1
Fateh-Moghadam, A1
Ichino, Y1
Obuchi, M1
Suko, K1
Ishikawa, T1
Hirshaut, Y1
Kesselheim, H1
Sampi, K1
Honda, T1
Hattori, M1
Trishkina, EA1
Gershanovich, ML1
Pavlov, KA1
Danova, LA1
Labkovskiĭ, BM1
Cohen, M1
Hill, CA1
Cangir, A1
Sullivan, MP1
Brodeur, GM1
Williams, DL1
Look, AT1
Bowman, WP1
Kalwinsky, DK1
Boyd, NF1
Campbell, JE1
Germanson, T1
Thomson, DB1
Sutherland, DJ1
Meakin, JW1
Foley, JF1
Kessinger, MA1
Lemon, HM1
Leung, F1
Fam, AG1
Osoba, D1
Cavalli, F2
Alberto, P5
Jungi, F1
Brunner, K1
Martz, G8
Beer, M1
Jungi, WF2
Obrecht, JP1
Mermillod, B1
Brunner, KW8
Tormey, DC7
Gelman, R2
Band, PR1
Sears, M1
Rosenthal, SN1
DeWys, W1
Perlia, C1
Rice, MA1
Ahmann, DL3
Green, SJ1
Bisel, HF2
Ingle, JN2
Hahn, RG2
Lee, RA2
Edmonson, JH2
Falkson, HC2
Goldhirsch, A2
Joss, R1
Sonntag, RW3
Tschopp, L1
Smalley, RV3
Bartolucci, AA2
Evans, WK1
Thompson, DM1
Simpson, WJ1
Feld, R1
Phillips, MJ1
Osborne, CK2
Knight, WA1
Yochmowitz, MG1
McGuire, WL1
Gelber, RD1
Price, KN1
Castiglione, M1
Coates, AS1
Rudenstam, CM1
Collins, J1
Lindtner, J1
Hacking, A1
Marini, G1
Park, HS1
Shin, DM1
Lee, JS1
Komaki, R1
Pollack, A1
Putnam, JB1
Cox, JD1
Hong, WK1
Miyata, T1
Fujimoto, Y1
Fukushima, M1
Torisu, M1
Tanaka, M1
Knechtle, SJ1
Kalayoglu, M1
D'Alessandro, AM1
Pirsch, JD1
Hoffmann, RM1
Sollinger, HW1
Belzer, FO1
Bishop, JF2
Dewar, J1
Toner, G1
Tattersall, MH1
Olver, I1
Ackland, S1
Kennedy, I1
Goldstein, D1
Walpole, E1
Levi, J1
Stephenson, J1
Gelman, RS2
Pandya, KJ1
Tormey, D2
Cummings, FJ3
Abeloff, MD2
Karakuş, S1
Yalçin, S1
Güler, N1
Cöplü, L1
Ayhan, A1
Hartmann, JT1
Quietzsch, D1
Daikeler, T1
Kollmannsberger, C1
Mayer, F1
Kanz, L1
Bokemeyer, C1
Cao, TM1
Negrin, RS1
Stockerl-Goldstein, KE1
Johnston, LJ1
Shizuru, JA1
Taylor, TL1
Rizk, NW1
Wong, RM1
Blume, KG1
Hu, WW1
Ghate, JV1
Turner, ML1
Rudek, MA1
Dahut, W1
Dyer, V1
Pluda, JM1
Reed, E1
Laver, JH1
Mahmoud, H1
Pick, TE1
Hutchinson, RE1
Weinstein, HJ1
Schwenn, M1
Weitzman, S1
Murphy, SB1
Ochoa, S1
Shuster, JJ1
Farrell, GC1
Joshua, DE1
Uren, RF1
Baird, PJ1
Perkins, KW1
Kronenberg, H1
Just-Viera, JO1
Silva, JE1
Frey, F1
Marone, C1
Zimmermann, A1
Rossof, AH1
Kerr, RO1
Braine, HG1
Coltman, CA3
Wagner, HP1
Gailani, S1
Seon, BK1
Henderson, ES1
Au, WY1
Blechschmidt, CM1
Schermuly, W1
Schwartz, AD1
Lee, H1
Baum, ES1
Sterioff, S1
Rios, CN1
Zachary, JB1
Williams, GM1
Livingston, RB1
Nüvemann, M1
Fernholz, HJ1
Frik, W1
Carbone, PP4
Bauer, M1
Band, P1
Corder, MP1
Sheets, RF1
Stone, WH1
Flannery, EP1
Justice, GR1
Herbst, KD1
Senn, HJ6
Obrecht, P3
Maurice, P1
Carpenter, J2
Bartolucci, A1
Vogel, C1
Krauss, S1
Mouridsen, HT4
Palshof, T3
Muss, HB2
White, DR2
Cooper, MR2
Richards, F2
Spurr, CL2
Mauer, AM1
Frederiksen, PL2
Joergensen, ST1
Roesdahl, K1
Thomsen, J1
Stuart, JJ1
Jackson, DV1
Rhyne, L1
Posner, JB1
Howieson, J1
Cvitkovic, E1
Wiltshaw, E1
Allegra, JC1
Lippman, ME1
Dietz, R1
Tkocz, HJ1
Tsiliacos, SC1
Athanasiou, AE1
Wallace, EZ1
Rosman, PM1
Balthazar, A1
Sacerdote, A1
Sanz, MA1
Mayans, J1
Martínez, J1
Caballero, O1
Marty, ML1
Rosner, D5
Snyderman, M1
Nemoto, T5
Estapé, J1
Millá, A1
Prats, M1
Herranz, M1
Visa, J1
Buell, GV1
Saiers, JH1
Saiki, JH1
Bergreen, PW1
Diaz, R1
Dao, T1
Sponzo, R1
Cunningham, T1
Horton, J2
Simon, R1
Petersen, M1
Taylor, JD1
Steinbaum, FL1
De Jager, RL1
Krakoff, IH1
Bugarski, M1
Vuletić, L1
Boberić, J1
Milosavljević, A1
Dilparić, S1
Tomin, R1
Naumović, P1
Almog, C1
Pik, A1
Weisberg, D1
Herczeg, E1
Shellito, J1
Khandekar, JD1
McKeever, WP1
Vick, NA1
Sitarz, AL1
Santulli, TV1
Wigger, HJ1
Berdon, WE1
Haskell, CM1
Sparks, FC1
Graze, PR1
Korenman, SG1
Kane, RD2
Stocks, LH1
Paulson, DF2
O'Connell, MJ1
Hansen, M1
Osterlind, K1
Hansen, HH1
Mouridsen, H1
Brahm, M1
Rahbek, I1
Weller, SA1
Glatstein, E1
Kaplan, HS2
Rosenberg, SA2
Murphy, S1
Huguley, CM1
Barndt, J1
Dao, TL1
Mickey, DD1
Dalquen, P1
Bertel, O1
Staehelin, HB1
Ho, EP1
Lieber, A1
DeLand, FH1
Maruyama, Y1
Lozada, JA1
Grillo-López, A1
Vélez-Garciá, E1
Scavino, HF1
George, JN1
Sears, DA1
Mitchell, MS1
Gallmeier, WM1
Bruntsch, U2
Schmidt, CG2
Farmer, W1
Ravin, C1
Schachter, EN1
Lewis, RA1
Clark, RB1
Garfein, OB1
Ramirez, G3
Klotz, J1
Strawitz, JG1
Wilson, WL1
Cornell, GN1
Madden, RE1
Minton, JP1
Wollner, N2
Burchenal, JH2
Lieberman, PH2
Exelby, PR1
D'Angio, GJ1
Murphy, ML2
Exelby, P1
D'Angio, G1
Canellos, GP3
DeVita, VT3
Gold, GL2
Chabner, BA2
Schein, PS2
Young, RC3
Fosså, SD3
Lehne, G1
Gunderson, R2
Hjelmaas, U1
Holdener, EE1
Celsing, F1
Hast, R1
Stenke, L1
Hansson, H1
Pisa, P1
Rischin, D1
Olver, IN1
Laidlaw, CR1
Zimet, A1
Jeal, P1
Dipell, JF1
Jensen, JL1
Goel, R1
Venner, PM1
Spitzer, G1
Martino, S1
Samal, BA1
Redman, B1
Flaherty, L1
Kraut, M1
Simon, M1
Valdivieso, M1
Tomek, R1
Moe, B1
Gray, R1
Gilchrist, K1
Grage, T1
Wolter, J1
Woll, JE1
Kline, JC1
Palta, M1
Davis, TE2
Love, RR1
Yahalom, J1
Biran, S1
Sulkes, A1
Baillet, F1
Housset, M1
Dessard-Diana, B1
Jacquillat, C1
Michel-Langlet, P1
Alapetite, C1
Marschke, RF1
Schaid, DJ1
Krook, JE1
Mailliard, JA1
Cullinan, SA1
Pfeifle, DM1
Votava, HJ1
Ebbert, LP1
Windschitl, HE1
Tannock, I1
Gospodarowicz, M1
Meakin, W1
Panzarella, T1
Stewart, L1
Rider, W1
Schoen, HD1
Wendt, T1
Potrebica, V1
Taylor, R1
Tandan, R1
Roberts, J1
DiCostanzo, DP1
Sharma, K1
Fries, T1
Jakobsen, A1
Møller, KA1
Andersen, AP1
Brincker, H1
Dombernowsky, P1
Hansen, PV1
Hesselius, I1
Kjaer, M1
Friess, GG1
McCracken, JD1
Troxell, ML1
Pazdur, R1
Eyre, HJ1
Romero, A1
Rabinovich, MG1
Pérez, JE1
Macchiavelli, M1
Leone, BA1
Strauss, E1
Goldar, D1
Alvarez, LA1
Vallejo, C1
Loprinzi, CL1
Rasmussen, P1
Chang, AY1
Vogel, CL1
Raney, M1
Pretorius, FJ1
Petru, E1
Schmähl, D1
Lane, WW1
Carter, SK1
Schneck, SA1
Penn, I5
Stutz, FH3
Blom, J3
Sievers, DB1
Donovan, AJ2
Tashima, CK1
van der Werf-Messing, B1
Shehata, WM1
Hendrickson, FR1
Hindo, WA1
Jacobsson, S1
Linell, F1
Rausing, A1
Schell, HW1
Cressy, NL1
Stephens, PJ1
Hudson, P1
Mendoza, CB1
Gerwig, WH1
Watne, AL1
Gleason, TH1
Hamlin, WB1
De Souza e Silva, NA1
Wilson, DM1
Davis, HL3
Wiseley, AN1
Ansfield, FJ3
Farber, S1
Marks, IN1
Bank, S1
Louw, JH1
Shames, JM1
Dhurandhar, NR1
Blackard, WG1
Mitchell, ML1
Ernesti, M1
Raben, MS1
Scaliter, H1
Starzl, TE4
Porter, KA1
Brettschneider, L2
Bell, P1
Putnam, CW3
McGuire, RL1
Gorins, A1
Bloch-Michel, H1
Dussart, N1
Aristoff, H1
Ley, R1
Vanderhoeft, P1
Karkos, J1
Corman, J2
Groth, CG1
Halgrimson, CG2
Schroter, G1
Gustafsson, A1
Robertson, GL1
Bhoopalam, N1
Zelkowitz, LJ1
Tolloczko, T1
Wasiutyński, A1
Palva, T1
Palva, A1
Dammert, K1
Karma, P1
Mendes da Costa, P1
Jortay, A1
Noterman, J1
Byland, W1
Nagel, G1
Peterson, LJ1
Grimes, JH1
Dees, JE1
Anderson, EE1
Pouillart, P1
Schwarzenberg, L1
Mathé, G1
Schneider, M1
Jasmin, C1
Hayat, M1
Weiner, R1
de Vassal, F1
Amiel, JL1
Beyer, HP1
Fajbisowicz, S1
Mayr, AC1
Smith, P1
Nagel, GA2
Prout, MN1
McKenna, PJ1
Cole, DR1
Korbitz, BC2
Willoughby, ML1
Barsel', VA1
Matveev, BP1
Williams, R1
Smith, MG1
Booth, A1
Groth, C1
Melchert, F1
Brennan, MJ1
Stein, RS1
Moran, EM1
Desser, RK1
Miller, JB1
Golomb, HM1
Ultmann, JE1
Buckle, R1
Fairley, GH1
Freeman, JE1
Lokich, JJ1
Skarin, AT3
Höffken, K1
Hornung, G1
Becker, G1
Oproiu, A1
Goldenberg, IS1
McMahan, CA1
Escher, GC1
Volk, H1
Olson, KB1
Barb, U1
Vielberg, H1
Hoppe, D1
Bronsch, T1
Gudowski, J1
Lewis, MB1
Nunes, LB1
Powell, DE1
Shnider, BI1
Kaufman, S1
Goldstein, M1
Sugarbaker, PH1
Wilson, RE2
Spigel, SC1
Costanzi, JJ1
Pole, JG1
van Kaick, G1
Drings, P1
Fritsch, H1
Moskwa, G1
Lee, JM1
Lenhard, RE1
Baker, RR1
Steward, AM1
Nixon, D1
Zamcheck, N1
Aisenberg, A1
Andaloro, VA1
Babott, D1
Billund, JK1
Burton, JL1
Greaves, MW1
Walker, D1
Gill, TJ1
Corson, JM1
Greally, JF1
Theologides, A1
Kennedy, BJ1
Gamble, JF1
Fuller, LM1
Butler, JJ1
Shullenberger, CC1
Beck, W1
Barnard, CN1
Schrire, V1
Hammond, W1
Leb, DE1
Howell, RS1
Scott, WP1
Schaison, G1
Karb, K1
Reynolds, ES1
King, WW1
Cox, CE1
Boyce, WH1
Lleander, VC1
Goldstein, G1
Horsley, JS1
Shingleton, WW1
Sedransk, N1
Johnson, RO1
Moore, MR1
Bull, JM1
Jones, SE1
Gottlieb, JA1
Frei, E1
Luce, JK1
Arseneau, JC1
Sponzo, RW1
Levin, DL1
Schnipper, LE1
Bonner, H1
Johnson, RE1
Lee, CA1
Lloyd, HM1
Religa, H1
Sosin, A1
Czechowicz, Z1
Röthlisberger, C1
Donath, A1
Poretti, GG1
Zuppinger, A1
Gossart, R1
Kulakowski, S1
Achslogh, J1
Malherbe, A1
Bardana, EJ1
Pirofsky, B1
Májský, A1
Jakoubková, J2
Piro, AJ1
Aliapoulios, MA1
Moore, FD1
Finklestein, JZ1
Ekert, H1
Isaacs, H1
Higgins, G1
Abrahámová, J1
Havránková, N1
Wendel, H1
Kochan, E1
Kröger, W1
Walther, H1
Sharma, TC1
Huvos, AG1
Grabstald, H1
Wagle, DG1
Murphy, GP1
Ryan, SJ1
Frank, RN1
Green, WR1
Vansant, JH1
Payne, RL1
Wheeler, JR1
Harris, CC1
Smith, JP1
Boronow, RC1
Herter, FP1
Mulcare, RJ1
McCarthy, JG1
Gump, FE1
Ukai, M1
Buckley, K1
Wheeler, B1
Szreder, W1
Firat, D1
Olshin, S1
Kreiger, AE1
Meyer, D1
Smith, TR1
Riemer, K1
Neubauer, W1
Moccetti, T1
Mason, DT1
Stewart, JG1
Skinner, LG1
O'Connor, PJ1
Bethune, JE1
Berne, TV1
Schwarz, G1
Hoffmeister, W1
Loewe, KR1
Doorenbos, H1

Clinical Trials (41)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cance[NCT02257736]Phase 3982 participants (Actual)Interventional2014-11-30Active, not recruiting
Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patie[NCT02813408]226 participants (Actual)Observational2016-05-03Completed
A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer[NCT02125357]Phase 2202 participants (Actual)Interventional2014-09-30Completed
A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622]Phase 2100 participants (Anticipated)Interventional2020-10-07Recruiting
A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)[NCT01715285]Phase 31,209 participants (Actual)Interventional2013-02-12Completed
A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predom[NCT02043678]Phase 3806 participants (Actual)Interventional2014-03-30Active, not recruiting
Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487]Early Phase 142 participants (Anticipated)Interventional2024-01-01Not yet recruiting
A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer[NCT01576172]Phase 2159 participants (Actual)Interventional2012-03-30Completed
Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy[NCT00331344]Phase 1/Phase 2100 participants (Actual)Interventional2006-04-30Completed
A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen[NCT00676650]Phase 3873 participants (Actual)Interventional2008-07-31Terminated (stopped due to Study A6181120 was prematurely discontinued due to futility on 27 September 2010. No new or unexpected safety issues were identified.)
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer[NCT00887198]Phase 31,088 participants (Actual)Interventional2009-04-28Completed
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours Using the Quadratic Phenotypic Optimization Platform (QPOP) and an Artificial Intelligence-based Platform (CURATE.AI)[NCT05381038]Phase 1/Phase 210 participants (Anticipated)Interventional2022-06-30Not yet recruiting
A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen.[NCT00503984]Phase 1/Phase 222 participants (Actual)Interventional2007-05-31Terminated (stopped due to Withdrawal of Funding)
Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy[NCT03941496]Phase 1/Phase 20 participants (Actual)Interventional2022-10-31Withdrawn (stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.)
A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma[NCT01068392]Phase 242 participants (Actual)Interventional2009-10-31Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy[NCT00638690]Phase 31,195 participants (Actual)Interventional2008-05-31Completed
Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib Upon Progression to Chemotherapy and Next Generation Hormonal Agents: a Phase II Study[NCT05265988]Phase 232 participants (Anticipated)Interventional2021-10-29Recruiting
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100[NCT01605227]Phase 31,028 participants (Actual)Interventional2012-07-31Completed
A Pilot Study of Abiraterone Acetate in African American/Black Patients With Castration Resistant Prostate Cancer[NCT01735396]Phase 211 participants (Actual)Interventional2012-12-31Terminated (stopped due to poor accrual)
An Open-Label, Multi-Centre, Randomised, Phase Ib Study to Investigate the Safety and Efficacy of RO5072759 Given in Combination With CHOP, FC or Bendamustine Chemotherapy in Patients With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma[NCT00825149]Phase 1137 participants (Actual)Interventional2009-02-28Completed
A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067]Phase 1/Phase 29 participants (Actual)Interventional2013-08-14Completed
A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis[NCT03114254]Phase 217 participants (Actual)Interventional2014-12-05Completed
Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC[NCT03176381]110 participants (Actual)Observational2017-05-05Completed
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide[NCT01981707]Phase 2/Phase 312 participants (Actual)Interventional2013-12-31Terminated (stopped due to enrollment default)
Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221]39 participants (Actual)Interventional2013-05-31Completed
Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer[NCT04225910]Early Phase 120 participants (Anticipated)Interventional2020-01-01Not yet recruiting
Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels[NCT02867020]Phase 2128 participants (Actual)Interventional2017-10-11Completed
A Single-center, Phase II Neoadjuvant Study of Abiraterone Acetate in the Treatment of Intraductal Carcinoma of the Prostate[NCT04736108]Phase 250 participants (Anticipated)Interventional2021-05-31Not yet recruiting
A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930]Phase 16 participants (Actual)Interventional2019-05-01Terminated (stopped due to Sponsor discontinued the drug)
A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease[NCT01120470]Phase 274 participants (Actual)Interventional2010-09-30Completed
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma[NCT03145285]Phase 210 participants (Anticipated)Interventional2017-04-18Active, not recruiting
Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.[NCT04962919]590 participants (Anticipated)Observational2020-01-14Recruiting
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)[NCT01578655]Phase 3630 participants (Actual)Interventional2012-08-31Completed
Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer[NCT00327340]Phase 270 participants (Actual)Interventional2006-07-31Completed
A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.[NCT03103724]Phase 268 participants (Actual)Interventional2017-03-16Completed
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer: An Open-label, Randomized, Cross-Over Trial.[NCT04409288]Phase 3146 participants (Anticipated)Interventional2020-07-20Recruiting
A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)[NCT03737370]Phase 125 participants (Anticipated)Interventional2018-01-30Recruiting
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791]Phase 1/Phase 230 participants (Anticipated)Interventional2023-11-30Not yet recruiting
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001]Phase 3770 participants (Actual)Interventional1999-10-31Completed
Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the BK0023 Injectable Formulation vs. Neupogen®[NCT01933971]Phase 1102 participants (Actual)Interventional2007-06-30Completed
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients[NCT00001384]Phase 235 participants Interventional1994-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Overall Survival (OS)

The OS was defined as the time from randomization to date of death from any cause. (NCT02257736)
Timeframe: Up to 5 years and 10 months

Interventionmonths (Median)
Placebo+ Abiraterone Acetate - Prednisolone33.71
Apalutamide + Abiraterone Acetate - Prednisolone36.17

Radiographic Progression-free Survival (rPFS)

The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. (NCT02257736)
Timeframe: Up to 3 years and 4 months

Interventionmonths (Median)
Placebo+ Abiraterone Acetate - Prednisolone16.59
Apalutamide + Abiraterone Acetate - Prednisolone23.98

Time to Chronic Opioid Use

Time to chronic opioid use was defined as the time from date of randomization to the first date of opioid use. (NCT02257736)
Timeframe: Up to 5 years and 10 months

Interventionmonths (Median)
Placebo+ Abiraterone Acetate - Prednisolone53.26
Apalutamide + Abiraterone Acetate - Prednisolone46.98

Time to Initiation of Cytotoxic Chemotherapy

Time to initiation of cytotoxic chemotherapy was defined as the time from date of randomization to the date of initiation of cytotoxic chemotherapy. (NCT02257736)
Timeframe: Up to 5 years and 10 months

Interventionmonths (Median)
Placebo+ Abiraterone Acetate - Prednisolone34.23
Apalutamide + Abiraterone Acetate - Prednisolone36.11

Time to Pain Progression

"Time to pain progression: time from randomization to first date that participant either experienced an increase by 2 points from baseline in Brief Pain Inventory Short Form (BPI-SF) worst pain intensity item (item 3) or Case Report Form (CRF) pain, observed at 2 consecutive evaluations >=4 wks apart, or initiation of chronic opioids as defined in time to chronic opioid use, whichever occurred first. BPI-SF is a self-administered questionnaire developed to assess severity of pain and impact of pain on daily functions. Item 3(worst pain intensity) asks participants to rate worst pain in prior 7-days on a 0-10 numeric rating scale, where 0 indicates No pain and 10 indicates Pain as bad as you can imagine. A lower score is better.CRF pain refers to participant's response to global pain assessment How would you rate your pain over the past 7 days?with a scale of 0(No pain) to 10(Pain as bad as you can imagine),that is systematically reported and recorded on the eCRF." (NCT02257736)
Timeframe: Up to 5 years and 10 months

Interventionmonths (Median)
Placebo+ Abiraterone Acetate - Prednisolone26.51
Apalutamide + Abiraterone Acetate - Prednisolone21.82

Overall Survival (OS)

Overall survival was defined as the time from randomization to date of death from any cause. (NCT01715285)
Timeframe: Up to 66 months

Interventionmonths (Median)
Abiraterone Acetate+Prednisone+ADT53.32
Placebo + ADT36.53

Radiographic Progression-Free Survival (PFS)

Radiographic PFS was defined as the time (in months) interval from randomization to the first date of radiographic progression or death. Radiographic progression included progression by bone scan (according to modified Prostate Cancer Working Group 2 [PCWG2] criteria), defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria). As per the RECIST 1.1 guideline, progression requires a 20 percent (%) increase in the sum of diameters of all target lesions and a minimum absolute increase of 5 millimeter (mm) in the sum as compared to nadir sum of diameter. (NCT01715285)
Timeframe: Up to 44 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT33.02
Placebo + ADT14.78

Time to Initiation of Chemotherapy

Time to initiation of chemotherapy was defined as the time (in months) interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months

Interventionmonths (Median)
Abiraterone Acetate+Prednisone+ADTNA
Placebo + ADT57.59

Time to Pain Progression

"Time to pain progression was defined as the time (in months) interval from randomization to the first date a participant experienced a greater than or equal to (>=) 30 percent (%) increase in Brief Pain Inventory-Short Form (BPI-SF) from baseline in the BPI-SF worst pain intensity (Item 3) observed at 2 consecutive evaluations (>=4) weeks apart. BPI-SF was an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score ranged from 0 to 10 with 0 representing no pain and 10 representing pain as bad as you can imagine." (NCT01715285)
Timeframe: Up to 66 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT47.41
Placebo + ADT16.62

Time to Prostate-Specific Antigen (PSA) Progression

Time to PSA progression was defined as the time (in months) interval from the date of randomization to the date of PSA progression, according to PCWG2 criteria. PCWG2 defines PSA progression as the date that a 25 percent (%) or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL) or more from the nadir is documented, which is confirmed by a second value obtained 3 or more weeks later. (NCT01715285)
Timeframe: Up to 66 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT33.31
Placebo + ADT7.43

Time to Skeletal-Related Event

Time to skeletal-related event was defined as the earliest of the following: clinical or pathological fracture, spinal cord compression, palliative radiation to bone, or surgery to bone. (NCT01715285)
Timeframe: Up to 66 months

Interventionmonths (Median)
Abiraterone Acetate+Prednisone+ADTNA
Placebo + ADTNA

Time to Subsequent Therapy for Prostate Cancer

Time to subsequent therapy was defined as the time (in months) interval from the date of randomization to the date of initiation of subsequent therapy for prostate cancer. (NCT01715285)
Timeframe: Up to 66 months

InterventionMonths (Median)
Abiraterone Acetate+Prednisone+ADT54.87
Placebo + ADT21.22

Number of Participants With Any Treatment-emergent Additional Primary Malignancies

Treatment-emergent additional primary malignancies were adverse events identified as additional primary malignancies that occurred after start of study treatment until the end of the treatment period. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months

InterventionParticipants (Count of Participants)
Radium-223 Dichloride + Abi/Pred26
Placebo + Abi/Pred25

Number of Participants With Treatment-emergent Bone Fractures

Treatment-emergent fractures were adverse events identified as fractures that occurred after start of study treatment until the end of the treatment period. All bone fractures and bone-associated events (e.g., osteoporosis) were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: From start of study treatment until 4 weeks after last study treatment, up to 65 months

InterventionParticipants (Count of Participants)
Radium-223 Dichloride + Abi/Pred107
Placebo + Abi/Pred49

Overall Survival (OS)

OS was defined as the time (months) from the date of randomization to the date of death due to any cause. Subjects alive at the survival cut-off date were censored at the last date known to be alive. (NCT02043678)
Timeframe: From randomization until death from any cause, up to 67 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred30.1
Placebo + Abi/Pred34.8

Radiological Progression Free Survival (rPFS)

rPFS was defined as the time (months) from the date of randomization to the date of confirmed radiological progression or death (if death occurred before progression) based on independent assessment. (NCT02043678)
Timeframe: From randomization until the date of confirmed radiological progression or death, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred11.2
Placebo + Abi/Pred12.4

Symptomatic Skeletal Event Free Survival (SSE-FS)

SSE-FS was defined as time (months) from randomization to the earliest of onset date of skeletal symptoms treated with external beam radiotherapy (EBRT), onset date of pathological bone fracture, onset date of spinal cord compression, procedure date of tumor-related orthopedic surgery, or death from any cause. Subjects who died without prior SSE and ≥ 13 weeks after the last SSE assessment are censored at the last SSE assessment date. Subjects alive at the survival cut-off date are censored at the last date known to be alive. Subjects with multiple events are only counted for the category in which the first event occurred. If multiple SSE (component events) occur on the same date for 1 subject, the subject is only counted into 1 category in the order of: spinal cord compression > bone fracture > orthopedic surgery > EBRT. (NCT02043678)
Timeframe: From randomization until first onset of on-study symptomatic skeletal event (SSE) or death, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred22.3
Placebo + Abi/Pred26.0

Time to Cytotoxic Chemotherapy

Time to cytotoxic chemotherapy is time (months) from randomization to the earliest date of the first cytotoxic chemotherapy. Participants who have not started cytotoxic chemotherapy during the study were censored at the last assessment date. (NCT02043678)
Timeframe: From randomization until the date of first cytotoxic chemotherapy, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred29.5
Placebo + Abi/Pred28.5

Time to Opiate Use for Cancer Pain

Time to opiate use for cancer pain was defined as the interval from the date of randomization to the date of opiate use. (NCT02043678)
Timeframe: From randomization until the date of opiate use, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred19.0
Placebo + Abi/Pred22.6

Time to Pain Progression

Time to pain progression was defined as the interval from randomization to the first date a subject experienced pain progression, assessed by BPI-SF (see Baseline Characteristics) and defined as: an increase of 2 or more points in the average worst pain score (WPS) from baseline observed at 2 consecutive evaluations >= 4 weeks apart or initiation of short- or long-acting opioid use for pain for subjects with WPS 0 at baseline; an increase of 2 or more points in the average WPS from baseline observed at 2 consecutive evaluations ≥ 4 weeks apart and an average WPS of ≥ 4 OR initiation of short- or long-acting opioid use for pain for subjects with WPS 1 to 3 at baseline. Subjects without pain progression at the end of study are censored at the last date known to have not progressed: the last evaluation date for pain scores or last visit when recorded opiate use, whichever is last. Subjects with no on-study assessment or no baseline assessment are censored at the date of randomization. (NCT02043678)
Timeframe: From randomization until the date of pain progression based on pain score, up to 47 months

InterventionMonths (Median)
Radium-223 Dichloride + Abi/Pred14.4
Placebo + Abi/Pred18.7

Number of Participants With Any Study Drug-related Post-treatment Adverse Events Per Maximum Intensity

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4
Placebo + Abi/Pred3330
Radium-223 Dichloride + Abi/Pred3951

Number of Participants With Post-treatment Adverse Events

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. Any bleeding event occurring during the study was not documented as an AE because this event was planned to be captured in the assessment of efficacy. AEs that started after the treatment period were defined as post-treatment AEs. Drug-related AEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
Any eventsAny drug-related eventsAny chemotherapy-related eventsAny additional primary malignancies
Placebo + Abi/Pred1339347
Radium-223 Dichloride + Abi/Pred13818316

Number of Participants With Post-treatment Bone Fractures

Post-treatment fractures were adverse events identified as fractures that occured after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. All bone fractures and bone-associated events (e.g., osteoporosis), were reported as either AEs, or SAEs if the criteria of SAE were met, regardless of the investigator's causality assessment. (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
Lumbar vertebral fractureRib fractureSpinal compression fractureThoracic vertebral fractureTraumatic fractureOsteoporotic fracturePathological fracture
Placebo + Abi/Pred11112013
Radium-223 Dichloride + Abi/Pred00006612

Number of Participants With Post-treatment Chemotherapy-related Blood and Lymphatic System Disorders

Post-treatment blood and lymphatic system disorders were adverse events identified as blood and lymphatic system disorders that occurred after the end of the treatment period until participant died, was lost to follow-up, withdrew informed consent, actively objected to collection of further data, or was transitioned to the extended safety follow-up study. (NCT02043678)
Timeframe: After the treatment period, up to 46 months

,
InterventionParticipants (Count of Participants)
AnaemiaBone marrow failureFebrile neutropeniaLeukopeniaNeutropeniaPancytopeniaThrombocytopenia
Placebo + Abi/Pred4080312
Radium-223 Dichloride + Abi/Pred5151802

Number of Participants With Treatment-emergent Adverse Events

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Drug-related TEAEs or serious TEAEs were those with reasonable causal relationship to the study treatment decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months

,
InterventionParticipants (Count of Participants)
Any TEAEAny drug-related TEAERadium-223/Placebo-related TEAEAny serious TEAEAny drug-related serious TEAERadium-223/Placebo-related serious TEAE
Placebo + Abi/Pred38727192172297
Radium-223 Dichloride + Abi/Pred382265921753211

Number of Subjects With Radium-223/Placebo-related Treatment-emergent Adverse Events Per Maximum Intensity

"An adverse event (AE) was any untoward medical occurrence (i.e., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant in the study. A serious adverse event (SAE) was any untoward medical occurrence that at any dose was resulting in death, was lifethreatening, requires hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity. AEs or SAEs occurring after start of study treatment until the end of the treatment period were defined as treatment-emergent AEs (TEAEs) or serious TEAEs. Radium-223/placebo-related TEAEs or serious TEAEs were those with reasonable causal relationship to radium-223 or placebo decided by the investigators." (NCT02043678)
Timeframe: From start of study treatment until the end of the treatment period, up to 65 months

,
InterventionParticipants (Count of Participants)
TEAE - Grade 1TEAE - Grade 2TEAE - Grade 3TEAE - Grade 4Serious TEAE - Grade 2Serious TEAE - Grade 3Serious TEAE - Grade 4
Placebo + Abi/Pred5324132052
Radium-223 Dichloride + Abi/Pred4428191380

Confirmed Prostate-specific Antigen (PSA) Response Rate

50% or greater decline in PSA from baseline. (NCT01576172)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Arm I (Abiraterone Acetate and Prednisone)46
Arm II (Abiraterone Acetate, Prednisone, and Veliparib)55

Grade 4 or 5 Adverse Events

Grade 4 or greater toxicity graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 at least possibly related to treatment. (NCT01576172)
Timeframe: 30 days after completion of study treatment

InterventionParticipants (Count of Participants)
Arm I (Abiraterone Acetate and Prednisone)1
Arm II (Abiraterone Acetate, Prednisone, and Veliparib)3

Objective Response Rates in Patients With Measurable Disease.

Overall response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01576172)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Arm I (Abiraterone Acetate and Prednisone)18
Arm II (Abiraterone Acetate, Prednisone, and Veliparib)24

Progression-free Survival (PFS)

Time from randomization to disease progression or death. (NCT01576172)
Timeframe: Up to 42 months

Interventionmonths (Median)
Arm I (Abiraterone Acetate and Prednisone)10.1
Arm II (Abiraterone Acetate, Prednisone, and Veliparib)11.0

Rates of PSA Decline

Change in PSA from baseline to 12 weeks (NCT01576172)
Timeframe: 12 weeks

Interventionng/ml (Mean)
Arm I (Abiraterone Acetate and Prednisone)-41.1
Arm II (Abiraterone Acetate, Prednisone, and Veliparib)-52.9

Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).

Cohorts of 3 patients will be enrolled at each dose level; if 1 dose limiting toxicity (DLT) is observed then the cohort will be expanded to 6 patients. If a second DLT is observed, the previous dose level will be considered the maximum tolerated dose (MTD). If all observed DLT are due to neuropathy (specific to ixabepilone), then we would consider the previous dose level of Ixabepilone the MTD for that drug, and escalate mitoxantrone hydrochloride as described above to a maximum dose of 12 mg/m^2. Toxicities will be tabulated by grade for each dose cohort and overall for all patients accrued to the phase I study. (NCT00331344)
Timeframe: Course 1 (first 21 days)

InterventionParticipants (Count of Participants)
Phase I Group I0
Phase Group II0
Phase I Group III0
Phase I Group IV1
Phase I Group V2
Phase I Group VI2
Phase I Group Va0
Phase I Group VIa1

Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of > 50% (Phase II)

"Descriptive statistics will be calculated to characterize the disease and treatment factors including the proportion responding with a 95% confidence interval. If accrual is completed and more than 15 of 58 patients show > 50% Prostate Specific Antigen (PSA) declines after 3 courses, then the null hypothesis of a 20% response proportion will be rejected. PSA declines for individual patients will be plotted in the form of a waterfall diagram of maximal PSA declines.~58 patients were enrolled for phase II, two were ineligible so 56 patients were analyzed." (NCT00331344)
Timeframe: Every 3 courses until cancer progression/excessive toxicity or death

InterventionParticipants (Count of Participants)
Treatment (Combination Chemotherapy)25

Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)

This study will utilize the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 for adverse event monitoring and reporting. The cumulative grade 3 or higher adverse events for all dose levels are noted below and in the table of adverse events. (NCT00331344)
Timeframe: Every 21 days until cancer progression/excessive toxicity or death

InterventionAdverse Events (above threshold) (Number)
Phase I Treatment (Groups I-VIa)62

Time to Progression (Phase II)

Measured from the start of protocol therapy until RECIST (Response Evaluation Criteria In Solid Tumors Criteria) v1.0 progression. Progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00331344)
Timeframe: Every 3 months until cancer progression/excessive toxicity or death

Interventionmonths (Median)
Treatment (Combination Chemotherapy)4.4

Overall Survival (OS)

OS is the duration from randomization to death. For participants who were alive, overall survival was censored at the last contact. OS (in months) calculated as (date of death minus [-] date of randomization plus [+] 1) divided (/) 30.4. (NCT00676650)
Timeframe: Baseline up to 32 months

Interventionmonths (Median)
Sunitinib and Prednisone13.1
Placebo and Prednisone11.8

Percent of Participants With Objective Response (OR)

OR defined as the percent (%) of participants with confirmed Complete Response (CR) (disappearance of all target lesions) or Partial Response (PR) (>=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions) according to Response Evaluation Criteria in Solid Tumors (RECIST), relative to the full analysis population. Confirmed responses were those that persist on repeat imagining study >= 4 weeks after initial documentation of response. (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks

Interventionpercentage of participants (Number)
Sunitinib and Prednisone6.1
Placebo and Prednisone1.8

Progression-Free Survival (PFS)

PFS is the period from randomization until disease progression or death on study. PFS is censored on the date of last tumor assessment documenting absence of progressive disease. PFS (weeks) calculated as (first event date - randomization date + 1)/7.02 (NCT00676650)
Timeframe: Baseline, every 8 weeks up to 123 weeks

Interventionweeks (Median)
Sunitinib and Prednisone24.1
Placebo and Prednisone17.9

Overall Survival

Overall survival is defined as the time from randomization to date of death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to end of study (Month 60)

InterventionMonths (Median)
Abiraterone Acetate + Prednisone (AAP)34.66
Placebo30.29

Radiographic Progression-free Survival (rPFS)

The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)

InterventionMonths (Median)
Abiraterone Acetate + Prednisone (AAP)NA
Placebo8.28

Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point

The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)

InterventionMonths (Median)
Abiraterone Acetate + Prednisone (AAP)12.29
Placebo10.87

Time to Initiation of Cytotoxic Chemotherapy

The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)

InterventionMonths (Median)
Abiraterone Acetate + Prednisone (AAP)25.17
Placebo16.82

Time to Opiate Use for Prostate Cancer Pain

The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first opiate use or end of study (Month 60)

InterventionMonths (Median)
Abiraterone Acetate + Prednisone (AAP)33.38
Placebo23.39

Time to Prostate-specific Antigen (PSA) Progression

The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)

InterventionMonths (Median)
Abiraterone Acetate + Prednisone (AAP)11.07
Placebo5.55

Number of Participants With Treatment Emergent Adverse Events

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. (NCT00887198)
Timeframe: From first dose of study drug up to 30 days after the last dose of study drug

,,
InterventionParticipants (Number)
With Treatment-Emergent Adverse EventsWith Treatment-Emergent Serious Adverse Events
Abiraterone Acetate + Prednisone (AAP)541208
Placebo524148
Placebo to Abiraterone Acetate9339

Duration of Response

Length of time from the date of first observation of complete response (CR) or partial response (PR) to the date of first observation of disease progression, according to prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 1 (PCWG1) criteria. PSA response according to PCWG1 is defined as an least 50 percent decline in PSA level from baseline that was maintained for at least three weeks. (NCT00503984)
Timeframe: Up to 4.5 years.

Interventionweeks (Median)
All Study Participants Achieving PSA Response20.5

Number of Participants Achieving Prostate-specific Antigen (PSA) Response.

Number of participants achieving prostate-specific antigen (PSA) response according to Prostate Cancer Working Group 1 (PCWG1) criteria. PSA response according to PCWG1 is defined as an least 50 percent decline in PSA level from baseline that was maintained for at least three weeks. (NCT00503984)
Timeframe: Up to 4.5 years.

Interventionparticipants (Number)
Phase 1: Level 1 - 75 Aza + 60 Doc0
Phase 1: Level 2 - 75 Aza + 75 Doc1
Phase 1: Level 3 - 100 Aza + 75 Doc2
Phase 1: Level 4 - 150 Aza + 75 Doc4
Phase 2 - Aza + Doc Initial RPTD3
Phase 2 - Aza + Doc Reduced RPTD0

Number of Participants Experiencing Adverse Events After Beginning Protocol Therapy.

(NCT00503984)
Timeframe: Up to 4.5 years

Interventionparticipants (Number)
Level 1 - 75 Aza + 60 Doc3
Level 2 - 75 Aza + 75 Doc4
Level 3 - 100 Aza + 75 Doc3
Level 4 - 150 Aza + 75 Doc12

Overall Survival (OS)

The time from the date of initiation of study treatment until date of death from any cause. (NCT00503984)
Timeframe: Up to 4.5 years.

Interventionmonths (Median)
All Study Participants19.5

Progression-Free Survival (PFS)

The time from the date of start of treatment until the first documented or confirmed disease progression, or death related to prostate cancer, whichever is earlier. (NCT00503984)
Timeframe: Up to 4.5 years

Interventionmonths (Median)
All Study Participants4.9

Number of Participants Achieving Complete Response (CR) or Partial Response (CR) to Protocol Therapy.

"Number of participants achieving Complete Response (CR) or Partial Response to protocol therapy according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 Criteria. Per RECIST 1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; " (NCT00503984)
Timeframe: Up to 4.5 years

,,,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)
Phase 1: Level 1 - 75 Aza + 60 Doc00
Phase 1: Level 3 - 100 Aza + 75 Doc10
Phase 1: Level 4 - 150 Aza + 75 Doc01
Phase 2 - Aza + Doc Initial RPTD01

Phase I - Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel in Combination With Prednisone. (Azacitidine and Docetaxel)

Determination of a safe and potentially efficacious phase II dose of azacitidine in combination with docetaxel and prednisone that can be used for the treatment of hormone refractory metastatic prostate cancer. (NCT00503984)
Timeframe: Up to 1.5 years

Interventionmg/m2 (Number)
Initial RPTD Azacitidine (mg/m2)Initial RPTD Docetaxel (mg/m2)Reduced RPTD Azacitidine (mg/m2)Reduced RPTD Docetaxel (mg/m2)
Phase 1 - Aza + Doc150757575

Phase I - Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel in Combination With Prednisone. (Prednisone)

Determination of a safe and potentially efficacious phase II dose of azacitidine in combination with docetaxel and prednisone that can be used for the treatment of hormone refractory metastatic prostate cancer. (NCT00503984)
Timeframe: Up to 1.5 years

Interventionmg (Number)
Initial RPTD Prednisone (mg)Reduced RPTD Prednisone (mg)
Phase 1 - Aza + Doc55

Number of Patients Achieving a Prostate-Specific Antigen Decline >=50%

A prostate-specific antigen (PSA) response was defined as a >=50% decline from baseline. (NCT00638690)
Timeframe: Up to 12 months

InterventionParticipants (Number)
Abiraterone Acetate232
Placebo22

Overall Survival

Overall survival is defined as the time interval from the date of randomization to the date of death from any cause. (NCT00638690)
Timeframe: Up to 60 months

InterventionDays (Median)
Abiraterone Acetate450.0
Placebo332.0

Radiographic Progression-free Survival

Radiographic progression-free survival is based on imaging studies according to modified Response Evaluation Criteria in Solid Tumors (RECIST): baseline lymph node size must be >=2.0 cm to be considered a target lesion; progression on bone scans with >=2 new lesions not consistent with tumor flare, confirmed on a second scan >=6 weeks later that shows >=1 additional new lesion. (NCT00638690)
Timeframe: Up to 11 months

InterventionDays (Median)
Abiraterone Acetate171.0
Placebo110.0

Time to Prostate-Specific Antigen Progression According to Prostate Specific Antigen Working Group Criteria

The time interval from the date of randomization to the date of the prostate-specific antigen (PSA) progression as defined in the protocol-specific Prostate Specific Antigen Working Group (PSAWG) criteria, namely, a PSA level of at least 5 ng/ml that has risen on at least 2 successive occasions, at least 2 weeks apart. (NCT00638690)
Timeframe: Up to 12 months

InterventionDays (Median)
Abiraterone Acetate309.0
Placebo200.0

Bone Scan Response (BSR)

BSR is defined as >=30% reduction in the bone scan lesion area (BSLA) compared with baseline. Confirmation of bone scan was not required for response or progression. Bone scans were evaluated by an independent radiology facility (IRF) for response. (NCT01605227)
Timeframe: BSR was measured at the end of Week 12 as determined by the IRF

Interventionpercentage of participants (Number)
Cabozantinib42
Prednisone3

Overall Survival (OS)

The primary analysis of OS is defined as the time from randomization to death due to any cause. Participants that had not died or were permanently lost to follow-up were censored at the last known date alive. Median OS was calculated using Kaplan-Meier estimates. Analysis for OS was performed after 614 events had occurred. (NCT01605227)
Timeframe: OS was measured from the time of randomization until 614 events, approximately 24 months after study start

Interventionmonths (Median)
Cabozantinib11.0
Prednisone9.8

Progression-free Survival (PFS)

The exploratory analysis of PFS is the time from randomization to date of first documented radiographic progression (bone and/or soft tissue) according to the investigator's assessment or death. PFS was defined per mRECIST 1.1 and included evaluation of measurable, nonmeasurable, target and nontarget lesions. A Kaplan-Meier analysis was performed to estimate the median duration. (NCT01605227)
Timeframe: Duration of PFS was defined as time from the date of randomization to earlier of date of radiographic progression (bone/andor soft tissue) according to the investigator's assessment or death, assessed for up to approximately 24 months

Interventionmonths (Median)
Cabozantinib5.6
Prednisone2.8

Number of Participants With ≥ 30% Change in PSA

The primary objective of this study is to determine a correlation between inherited genetic polymorphisms and antitumor activity (as defined by a decline in PSA of ≥ 30%) in AA patients with castration-resistant prostate cancer treated with Abiraterone. The primary endpoint is the percent change in PSA from baseline to 12 weeks. A decline of ≥ 30% will be correlated with germline SNPs. (NCT01735396)
Timeframe: baseline and 12 weeks

InterventionParticipants (Count of Participants)
Abiraterone Acetate9

Safety of Abiraterone

To determine the safety of abiraterone Adverse events as defined by CTCAE v4. Number of participants with serious adverse events grade 4 or 5 (NCT01735396)
Timeframe: up to 12 weeks

InterventionParticipants (Count of Participants)
Abiraterone Acetate0

Response Assessment

Post-treatment changes in measurable disease by RECIST - Response Evaluation Criteria in Solid Tumors Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT01735396)
Timeframe: up to 12 weeks

InterventionParticipants (Count of Participants)
PRSD
Abiraterone Acetate91

Number of Participants With a PSA Value Equal to or Greater Than 25%

Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months

InterventionParticipants (Count of Participants)
Treatment (Alisertib, Abiraterone Acetate, Prednisone)3

Phase I: Frequency of Dose Limiting Toxicities of Alisertib, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1

Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days

InterventionParticipants (Count of Participants)
Treatment (Alisertib, Abiraterone Acetate, Prednisone)2

Feasibility of Treatment With Custirsen (OGX-011) in Combination With Second-line Chemotherapy Based on Prostate Specific Antigen (PSA) Response

PSA or prostate specific antigen is a marker for prostate cancer. A PSA response was defined as a decrease in PSA values of ≥ 50% relative to baseline on two or more consecutive measurements that were 4-6 weeks apart. (NCT00327340)
Timeframe: PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit and during off-treatment follow up (up to 27 months)

Interventionpercentage of participants (Number)
OGX-011 / Mitoxantrone/Prednisone17
OGX-011 / Docetaxel/Prednisone31

Feasibility of Treatment With OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second Line Chemotherapy Based on Time to Pain Progression

Time to pain progression was defined as the time (months) from the first dose of OGX-011 to the first documentation of pain or analgesic progression or initiation of palliative radiation therapy. Pain response was defined as either a decrease of at least two points on the 11-point Worst Pain Scale, without an increase in analgesic level, maintained for at least two consecutive measurements approximately three weeks apart -or- a decrease in analgesic level, without an increase in pain score, maintained for at least two consecutive measurements approximately three weeks apart. (NCT00327340)
Timeframe: Enrollment until pain progression (up to 21 months)

Interventionmonths (Number)
OGX-011 + Mitoxantrone + Prednisone5.2
OGX-011 + Docetaxel + Prednisone7.2

Relationship Between Changes in Serum Clusterin Levels and Change in Serum PSA Levels When OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone is Administered as Second Line Chemotherapy.

Serum clusterin samples were collected prior to receiving OGX-011 loading dose 1, prior to study treatment on Day 1 of each cycle, and at the end of treatment. PSA was evaluated at screening, on Day 1 of each cycle, at the end of treatment visit, and during off-treatment follow-up. PSA response was defined in the protocol as a decrease in PSA of ≥ 50% relative to baseline on two or more consecutive measurements 4-6 weeks apart. (NCT00327340)
Timeframe: Enrollment until disease progression (up to 13 months)

,
Interventionpercentage of participants (Number)
Minimum clusterin level < or = to 45 mcg/mLMinimum clusterin level > 45 mcg/mL
OGX-011 + Docetaxel + Prednisone247
OGX-011 + Mitoxantrone + Prednisone224

Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second-line Chemotherapy.

"Safety and tolerability were based on Adverse Events (AE) and Serious Adverse Events (SAE) graded using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE).~The CTCAE has 5 grades with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1=Mild AE; Grade 2=Moderate AE; Grade 3=Severe AE; Grade 4=Life-threatening or disabling AE; and Grade 5=Death related to AE." (NCT00327340)
Timeframe: Subjects were followed for safety from enrollment for up to 8 months (9 three-week cycles plus 30 days after end of treatment)

,
Interventionpercentage of participants (Number)
Percent of Subjects with Serious Adverse EventsPercent of Subjects with Grade 5 Adverse EventsPercent of Subjects with Grade 4 Adverse EventsPercent of Subjects with Grade 3 Adverse EventsPercent of Subjects with Grade 2 Adverse EventsPercent of Subjects with Grade 1 Adverse EventsPercent of Subjects who Discontinued Study Drug
OGX-011 + Docetaxel + Prednisone26415529810017
OGX-011 + Mitoxantrone + Prednisone261326708310022

Reviews

32 reviews available for prednisone and Metastase

ArticleYear
Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Expert review of anticancer therapy, 2020, Volume: 20, Issue:8

    Topics: Abiraterone Acetate; Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols;

2020
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
    Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:4

    Topics: Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednison

2021
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
    Urologic oncology, 2021, Volume: 39, Issue:11

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Pred

2021
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer.
    Drugs, 2017, Volume: 77, Issue:14

    Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxe

2017
Treatment of Castration-naive Metastatic Prostate Cancer.
    European urology focus, 2017, Volume: 3, Issue:6

    Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined

2017
Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials.
    Seminars in oncology, 2017, Volume: 44, Issue:5

    Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Surviv

2017
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
    PloS one, 2018, Volume: 13, Issue:12

    Topics: Aged; Antineoplastic Agents; Bias; Cost-Benefit Analysis; Humans; Male; Middle Aged; Mitoxantrone; N

2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 02-10, Volume: 37, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Black People; Clinical Trials, Phase III as Topic; D

2019
A drug safety evaluation of abiraterone acetate in the treatment of prostate cancer.
    Expert opinion on drug safety, 2019, Volume: 18, Issue:9

    Topics: Abiraterone Acetate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans;

2019
Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer.
    Drugs & aging, 2013, Volume: 30, Issue:5

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Europe;

2013
Second-line treatment of metastatic prostate cancer. Prednisone and radiotherapy for symptom relief.
    Prescrire international, 2013, Volume: 22, Issue:136

    Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

2013
[Use of abiraterone acetate in the treatment of patients with metastatic castration resistant prostate cancer and no prior chemotherapy: 3 case reports and literature review].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2014, Aug-18, Volume: 46, Issue:4

    Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progressio

2014
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Oct-20, Volume: 32, Issue:30

    Topics: Abiraterone Acetate; Androstadienes; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitri

2014
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
    The oncologist, 2014, Volume: 19, Issue:12

    Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis

2014
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
    Cancer treatment reviews, 2017, Volume: 55

    Topics: Age Factors; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi

2017
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Prostate cancer and prostatic diseases, 2010, Volume: 13, Issue:2

    Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Drug Administratio

2010
Primary NK/T cell lymphoma of the testis. A case report and review of the literature.
    Acta haematologica, 2003, Volume: 109, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamide; Doxorubici

2003
[ENDOCRINE TREATMENT OF METASTASISED MAMMARY CARCINOMA].
    Hormoner, 1963, Volume: 16

    Topics: Anabolic Agents; Androgens; Breast; Breast Neoplasms; Castration; Estrogens; Female; Humans; Hypophy

1963
ENDOCRINE TREATMENT OF METASTASISED MAMMARY CARCINOMA.
    Hormones, 1963, Volume: 16

    Topics: Anabolic Agents; Androgens; Breast; Breast Neoplasms; Castration; Estrogens; Female; Humans; Hypophy

1963
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
    Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Models,

2007
Chemotherapy in hormone-refractory prostate cancer.
    BJU international, 2008, Volume: 101 Suppl 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease P

2008
Management of metastatic prostate cancer: the crucial role of geriatric assessment.
    BJU international, 2008, Volume: 101 Suppl 2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docet

2008
[Recent developments in chemotherapy of malignant diseases].
    Wiener klinische Wochenschrift, 1982, Dec-10, Volume: 94, Issue:23

    Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

1982
The importance of dose intensity in chemotherapy of metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re

1984
The importance of dose intensity in chemotherapy of metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re

1984
The importance of dose intensity in chemotherapy of metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re

1984
The importance of dose intensity in chemotherapy of metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re

1984
Spontaneous rupture of splenic angiosarcoma: a case report of chemotherapeutic approach and review of the literature.
    Surgery today, 1993, Volume: 23, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub

1993
Chemotherapy of solid tumors. Recent advances.
    Postgraduate medicine, 1976, Volume: 59, Issue:2

    Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom

1976
[The state of hormone and chemotherapy in breast neoplasms].
    Schweizerische medizinische Wochenschrift, 1978, Sep-02, Volume: 108, Issue:35

    Topics: Androgens; Brain Neoplasms; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therap

1978
Autotransplantation in solid tumors.
    Blood reviews, 1991, Volume: 5, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms

1991
[Carcinoid: problems of pathology, biochemistry and therapy].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1971, Apr-12, Volume: 26, Issue:15

    Topics: Angiotensin II; Animals; Blood Pressure; Cyclophosphamide; Fluorouracil; Guinea Pigs; Histocytochemi

1971
[Hormone therapy of renal cancer].
    Voprosy onkologii, 1972, Volume: 18, Issue:6

    Topics: Acetates; Adenocarcinoma; Animals; Caproates; Castration; Cricetinae; Drug Synergism; Female; Femora

1972
Corticosteroids in the treatment of solid tumors.
    The Medical clinics of North America, 1973, Volume: 57, Issue:5

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Brain Edema; Brain Neoplasms; Breast Neoplasms; Chil

1973
Ectopic PTH syndrome, pseudohyperparathyroidism; hypercalcaemia of malignancy.
    Clinics in endocrinology and metabolism, 1974, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Adenoma; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcium; Carcinoma;

1974

Trials

119 trials available for prednisone and Metastase

ArticleYear
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    The Lancet. Oncology, 2021, Volume: 22, Issue:11

    Topics: Abiraterone Acetate; Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Proto

2021
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    European urology, 2020, Volume: 77, Issue:3

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemoth

2020
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam

2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam

2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam

2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzam

2019
Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study.
    Targeted oncology, 2019, Volume: 14, Issue:6

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia;

2019
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivatio
    European urology, 2020, Volume: 77, Issue:4

    Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Correlation of Data; Double-Blind

2020
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
    Japanese journal of clinical oncology, 2020, Jul-09, Volume: 50, Issue:7

    Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Do

2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer.
    BJU international, 2021, Volume: 127, Issue:4

    Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21

    Topics: Adrenal Cortex; Adult; Aged; Aged, 80 and over; Androgens; Androstenes; Antineoplastic Agents, Hormo

2021
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
    Anticancer research, 2017, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistan

2017
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 02-01, Volume: 29, Issue:2

    Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Prolifer

2018
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 87

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug

2017
Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
    Urologic oncology, 2018, Volume: 36, Issue:2

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Gastro

2018
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer.
    Investigational new drugs, 2018, Volume: 36, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Endpoint Determination; HSP27 Heat

2018
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 04-01, Volume: 36, Issue:10

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles

2018
Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
    Clinical genitourinary cancer, 2018, Volume: 16, Issue:3

    Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi

2018
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 07-01, Volume: 29, Issue:7

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression;

2018
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity.
    BMC cancer, 2018, Sep-21, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Cyclophospham

2018
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study.
    Japanese journal of clinical oncology, 2018, Nov-01, Volume: 48, Issue:11

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian

2018
Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2019
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    European urology, 2019, Volume: 75, Issue:6

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hu

2019
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2019, Volume: 20, Issue:3

    Topics: Abiraterone Acetate; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone N

2019
Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    The oncologist, 2019, Volume: 24, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Disease Progress

2019
Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302.
    The Prostate, 2019, Volume: 79, Issue:8

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
    The oncologist, 2019, Volume: 24, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikre

2019
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female;

2013
Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre

2013
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Cancer, 2011, Jun-01, Volume: 117, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Hum

2011
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2014, Volume: 17, Issue:1

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal

2014
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
    BJU international, 2015, Volume: 115, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Eto

2015
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jan-10, Volume: 32, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Di

2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    European urology, 2014, Volume: 66, Issue:5

    Topics: Abiraterone Acetate; Aged; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Che

2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
    European urology, 2015, Volume: 67, Issue:5

    Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle

2015
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
    Cancer, 2015, Apr-01, Volume: 121, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2015
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine

2015
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doce

2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-20, Volume: 33, Issue:12

    Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor;

2015
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Sep-01, Volume: 21, Issue:17

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Antigen-Presenting Cells; Antineoplastic Combined Chem

2015
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
    The Journal of urology, 2015, Volume: 194, Issue:5

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dis

2015
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.
    Leukemia & lymphoma, 2016, Volume: 57, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Resista

2016
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    European urology, 2016, Volume: 69, Issue:5

    Topics: Abiraterone Acetate; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic

2016
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother

2016
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother

2016
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother

2016
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Androstenols; Antineoplastic Combined Chemother

2016
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 56

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony

2016
Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    European urology, 2016, Volume: 70, Issue:5

    Topics: Abiraterone Acetate; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Di

2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-01, Volume: 34, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur

2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-01, Volume: 34, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur

2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-01, Volume: 34, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur

2016
Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-01, Volume: 34, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Sur

2016
Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.
    The oncologist, 2016, Volume: 21, Issue:12

    Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Black People; Humans; Mal

2016
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
    The oncologist, 2016, Volume: 21, Issue:11

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase

2016
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
    BJU international, 2008, Aug-05, Volume: 102, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male;

2008
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-10, Volume: 26, Issue:32

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch

2008
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy P

2009
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic A

2010
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance

2010
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplas

2010
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
    Investigational new drugs, 2011, Volume: 29, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2011
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
    Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:3

    Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoc

2010
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
    Future oncology (London, England), 2011, Volume: 7, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Cell Line, Tumor; Disease-Free Survival;

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemothera

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug

2011
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doce

2012
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:1

    Topics: Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Pr

2012
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Urologic oncology, 2013, Volume: 31, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Hu

2013
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; D

2012
[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2012, Volume: 50, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxant

2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
    Clinical genitourinary cancer, 2012, Volume: 10, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans;

2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Area Under Curv

2013
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2013
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Abiraterone Acetate; Androstadienes; Castration; Docetaxel; Fatigue; Humans; Male; Neoplasm Metastas

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Abiraterone in metastatic prostate cancer without previous chemotherapy.
    The New England journal of medicine, 2013, Jan-10, Volume: 368, Issue:2

    Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemot

2013
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-01, Volume: 21, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat

2003
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under

2003
Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
    Cancer, 2006, Sep-01, Volume: 107, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administr

2006
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Mal

2007
CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
    Cancer chemotherapy and pharmacology, 1984, Volume: 13, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical T

1984
Breast cancer 1984: state of the art.
    Indiana medicine : the journal of the Indiana State Medical Association, 1984, Volume: 77, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr

1984
Body weight and prognosis in breast cancer.
    Journal of the National Cancer Institute, 1981, Volume: 67, Issue:4

    Topics: Adult; Aged; Body Height; Body Weight; Breast Neoplasms; Castration; Female; Hormones; Humans; Menst

1981
Treatment of breast cancer with oral four-drug chemotherapy.
    Journal of surgical oncology, 1980, Volume: 14, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosph

1980
Hormono-chemotherapy versus hormonotherapy followed by chemotherapy in the treatment of disseminated breast cancer.
    European journal of cancer, 1980, Volume: Suppl 1

    Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Doxorubicin; Drug A

1980
[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].
    Schweizerische medizinische Wochenschrift, 1982, May-29, Volume: 112, Issue:22

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as T

1982
Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
    Cancer, 1982, Oct-01, Volume: 50, Issue:7

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubic

1982
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
    American journal of clinical oncology, 1982, Volume: 5, Issue:4

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphami

1982
Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
    Lancet (London, England), 1994, Feb-12, Volume: 343, Issue:8894

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju

1994
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 17

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1997
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosph

1998
Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer.
    Anti-cancer drugs, 1999, Volume: 10, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps

1999
Drug-induced lupus associated with COL-3: report of 3 cases.
    Archives of dermatology, 2001, Volume: 137, Issue:4

    Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Clobetasol; Female; Follow-Up Studies; Gluc

2001
Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
    Leukemia & lymphoma, 2001, Volume: 42, Issue:3

    Topics: Adolescent; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; D

2001
Chemotherapy of disseminated breast cancer. Current status and prospects.
    Cancer, 1977, Volume: 39, Issue:6 Suppl

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Dr

1977
Combined chemo- and hormonal therapy in advanced breast cancer.
    Cancer, 1977, Volume: 39, Issue:6 Suppl

    Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as Topic; Cycloph

1977
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
    Cancer, 1977, Volume: 40, Issue:2

    Topics: Agranulocytosis; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic;

1977
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.
    Progress in clinical and biological research, 1977, Volume: 12

    Topics: Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphami

1977
Combination chemotherapy in advanced breast cancer.: a randomized trial comparing a three-vs a five-drug program.
    Archives of internal medicine, 1977, Volume: 137, Issue:12

    Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Double-Blind Method; Drug Therapy, Com

1977
Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
    Cancer treatment reports, 1978, Volume: 62, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Resista

1978
Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
    Cancer, 1978, Volume: 42, Issue:5

    Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do

1978
Chemotherapy in the management of extramedullary plasmacytoma.
    Cancer chemotherapy and pharmacology, 1978, Volume: 1, Issue:3

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Humans;

1978
Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy.
    Cancer, 1978, Volume: 41, Issue:6

    Topics: Adrenalectomy; Aged; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Digestive System; Doxorubicin;

1978
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy.
    The New England journal of medicine, 1977, Aug-18, Volume: 297, Issue:7

    Topics: Adult; Age Factors; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Evalu

1977
[Cytostatic treatment of metastasizing breast cancer. A prospective controlled comparison between single drug and multiple drug chemotherapy].
    Ugeskrift for laeger, 1977, Oct-31, Volume: 139, Issue:44

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Comb

1977
Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.
    Cancer research, 1976, Volume: 36, Issue:11 Pt 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Adminis

1976
[Chemotherapy of metastasizing breast cancers. Indications and results].
    Deutsche medizinische Wochenschrift (1946), 1975, Jan-10, Volume: 100, Issue:2

    Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema

1975
Combination chemotherapy in breast cancer: a randomized study of 4 versus 5 drugs.
    Oncology, 1975, Volume: 32, Issue:3-4

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Methotrexate; Middle

1975
Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies.
    International journal of cancer, 1992, Apr-01, Volume: 50, Issue:6

    Topics: Antibody Formation; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Int

1992
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
    American journal of clinical oncology, 1992, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

1992
Autotransplantation in solid tumors.
    Blood reviews, 1991, Volume: 5, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms

1991
Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.
    Breast cancer research and treatment, 1990, Volume: 17, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1990
cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
    Tumori, 1990, Oct-31, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

1990
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
    Cancer, 1990, Jan-15, Volume: 65, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour

1990
Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
    Cancer, 1989, May-15, Volume: 63, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl

1989
Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
    Tumori, 1989, Apr-30, Volume: 75, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

1989
Medroxyprogesterone acetate and prednisone in advanced breast cancer. A randomized trial.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:9

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Injec

1986
Alternating versus sequential therapy in advanced breast cancer.
    Medicina, 1987, Volume: 47, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To

1987
Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Clinical

1986
Age as a prognostic factor in recurrent breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:5

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined

1986
A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer.
    Cancer, 1987, Mar-01, Volume: 59, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

1987
Adjuvant chemotherapy for breast cancer. Implications of clinical trials.
    Postgraduate medicine, 1985, Volume: 77, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr

1985
Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; C

1985
[Study of the metastasizing carcinoma of the breast (author's transl)].
    Therapeutische Umschau. Revue therapeutique, 1973, Volume: 30, Issue:9

    Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Hum

1973
[Control studies on the cytostatic combination therapy in metastasizing breast carcinoma].
    Der Internist, 1973, Volume: 14, Issue:12

    Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Synergism;

1973
Combination chemotherapy of lymphomas other than Hodgkin's disease.
    Annals of internal medicine, 1974, Volume: 81, Issue:5

    Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Drug Therapy, Combination

1974
Sequential radiotherapy and chemotherapy in the treatment of Hodgkin's disease. A progress report.
    Annals of internal medicine, 1972, Volume: 77, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzoates; Child; Drug Combinations; Female; Follow-

1972

Other Studies

279 other studies available for prednisone and Metastase

ArticleYear
Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer.
    The oncologist, 2023, 07-05, Volume: 28, Issue:7

    Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined

2023
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:7

    Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; B

2019
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
    British journal of cancer, 2019, Volume: 121, Issue:12

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docet

2019
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:11

    Topics: Androstenes; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male

2020
Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:4

    Topics: Abiraterone Acetate; Adult; Aged; Anti-Inflammatory Agents; Biomarkers, Tumor; Cell-Free Nucleic Aci

2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzami

2020
Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study.
    Anti-cancer drugs, 2020, Volume: 31, Issue:7

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined

2020
Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Urologia internationalis, 2021, Volume: 105, Issue:5-6

    Topics: Abiraterone Acetate; Antineoplastic Agents; Dexamethasone; Drug Substitution; Glucocorticoids; Human

2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
    Molecular oncology, 2021, Volume: 15, Issue:9

    Topics: Abiraterone Acetate; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Di

2021
Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
    Clinical genitourinary cancer, 2021, Volume: 19, Issue:5

    Topics: Abiraterone Acetate; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Markov Chains; Neopla

2021
Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
    JAMA network open, 2021, 07-01, Volume: 4, Issue:7

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Coho

2021
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    European urology, 2017, Volume: 72, Issue:1

    Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols

2017
A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.
    Oncotarget, 2017, Jul-18, Volume: 8, Issue:29

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap

2017
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
    Urology, 2017, Volume: 109

    Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Diseas

2017
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
    Anti-cancer drugs, 2017, Volume: 28, Issue:9

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hum

2017
High-dose chemotherapy with autologous stem cell transplantation following systemic chemotherapy, prophylactic intrathecal methotrexate, and radiotherapy prevents relapse and improves the outcome of advanced stage primary testicular lymphoma even with car
    Journal of clinical and experimental hematopathology : JCEH, 2017, Oct-12, Volume: 57, Issue:2

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Autografts;

2017
Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2018, Volume: 41, Issue:1

    Topics: Anemia, Hemolytic; Antibodies, Monoclonal, Humanized; CTLA-4 Antigen; Drug-Related Side Effects and

2018
Localized pretibial bullous pemphigoid arising in a patient on pembrolizumab for metastatic melanoma.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2018, Volume: 16, Issue:2

    Topics: Administration, Oral; Administration, Topical; Aged, 80 and over; Antibodies, Monoclonal, Humanized;

2018
Synchronous papillary thyroid cancer and non-Hodgkin lymphoma: Case report.
    Medicine, 2018, Volume: 97, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Clinical Decision-Making; Cycl

2018
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:5

    Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Hu

2018
Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
    Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem

2018
A case of pembrolizumab-induced localized organizing pneumonia.
    Scandinavian journal of immunology, 2018, Volume: 88, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Brain; Cryptogenic Organizing Pneumonia; Drug-Related Side Effect

2018
Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    European journal of haematology, 2018, Volume: 101, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th

2018
[Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
    Journal francais d'ophtalmologie, 2018, Volume: 41, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Huma

2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    BJU international, 2019, Volume: 123, Issue:2

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic D

2019
Fatigue, treatment satisfaction and health-related quality of life among patients receiving novel drugs suppressing androgen signalling for the treatment of metastatic castrate-resistant prostate cancer.
    European journal of cancer care, 2019, Volume: 28, Issue:1

    Topics: Abiraterone Acetate; Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemothera

2019
Germline Variant in
    Molecular cancer therapeutics, 2019, Volume: 18, Issue:3

    Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease

2019
Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer.
    The Prostate, 2019, Volume: 79, Issue:6

    Topics: Abiraterone Acetate; Aged; Antigens, Differentiation; Antineoplastic Agents; Antineoplastic Combined

2019
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma.
    Blood advances, 2019, 01-22, Volume: 3, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female;

2019
The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
    Cancer medicine, 2019, Volume: 8, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Doxorubic

2019
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:1

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Prot

2019
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 08-01, Volume: 37, Issue:22

    Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lu

2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    The Prostate, 2019, Volume: 79, Issue:13

    Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Prot

2019
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Antagonists; Androstadienes; Biomarkers, Tumo

2014
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:6

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use T

2014
[ON HODGKIN'S DISEASE. PERSONAL EXPERIENCE].
    Progresos de patologia y clinica, 1964, Volume: 11

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Biopsy; Chlorambucil; Classification; Hodg

1964
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmu

2015
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
    Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl

2014
Serum lactate dehydrogenase with a systemic inflammation score is useful for predicting response and survival in patients with newly diagnosed diffuse large B-cell lymphoma.
    Acta haematologica, 2015, Volume: 133, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C

2015
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Oct-01, Volume: 20, Issue:19

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;

2014
Corticosteroids and prostate cancer: friend or foe?
    European urology, 2015, Volume: 67, Issue:5

    Topics: Adrenal Cortex Hormones; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male;

2015
Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Oncotarget, 2015, Dec-08, Volume: 6, Issue:39

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cou

2015
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2016, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S

2016
Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
    Journal of medical economics, 2016, Volume: 19, Issue:8

    Topics: Abiraterone Acetate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Tri

2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
    European urology, 2016, Volume: 70, Issue:6

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Clinical Trials as Topic; H

2016
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    European urology, 2017, Volume: 71, Issue:4

    Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas

2017
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    European urology, 2017, Volume: 71, Issue:4

    Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas

2017
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    European urology, 2017, Volume: 71, Issue:4

    Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas

2017
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    European urology, 2017, Volume: 71, Issue:4

    Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplas

2017
Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2017, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Agents, Hormonal; Clinical Trials, Phase III as Topic; Humans; Kaplan-Meier Est

2017
MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
    Cancer, 2017, 04-01, Volume: 123, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C

2017
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
    Haematologica, 2017, Volume: 102, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bend

2017
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:4

    Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Eplerenone; Humans; Male;

2017
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2010, Volume: 13, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Anxiety; Area Under

2010
Breast lymphoma in Sjögren's syndrome complicated by acute monocular blindness.
    International journal of rheumatic diseases, 2010, Volume: 13, Issue:2

    Topics: Aged; Blindness; Breast Neoplasms; Combined Modality Therapy; Diagnosis, Differential; Female; Human

2010
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    BJU international, 2011, Volume: 107 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Epidemiologic

2011
Expanding treatment options for metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Hum

2011
Metronomic cyclophosphamide and methotrexate for breast cancer: enhanced efficacy by adding dalteparin and low-dose prednisone?
    Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Combined Modality T

2011
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
    Asian journal of andrology, 2011, Volume: 13, Issue:6

    Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, 08-25, Volume: 365, Issue:8

    Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combine

2011
Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
    Prescrire international, 2012, Volume: 21, Issue:128

    Topics: Androstenes; Androstenols; Drug Interactions; Humans; Male; Neoplasm Metastasis; Prednisone; Prostat

2012
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
    International journal of clinical oncology, 2013, Volume: 18, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Abiraterone and its place in the treatment of metastatic CRPC.
    Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:1

    Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Tria

2013
Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

2013
Clinical profiles of human immunodeficiency virus-associated lymphoma in Hong Kong.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2003, Volume: 9, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Ac

2003
Orbital inflammatory syndromes with systemic involvement may mimic metastatic disease.
    Ophthalmic plastic and reconstructive surgery, 2003, Volume: 19, Issue:4

    Topics: Blepharoptosis; Bone Diseases; Child; Diagnosis, Differential; Exophthalmos; Female; Glucocorticoids

2003
[Lost time].
    Geneeskundige gids, 1962, Nov-29, Volume: 40

    Topics: Breast Neoplasms; Humans; Neoplasm Metastasis; Prednisone

1962
[ENZYME DETERMINATIONS IN THE SERUM IN LIVER DISEASES. FUNCTION PATTERNS AS A MEANS OF DIAGNOSIS].
    Enzymologia biologica et clinica, 1963, Volume: 79

    Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholecystitis; C

1963
LEUKEMOGENIC THYMOMA: REPORT OF A UNIQUE CASE.
    American journal of clinical pathology, 1963, Volume: 40

    Topics: Adolescent; Bone Marrow; Chlorothiazide; Humans; Leukemia; Mediastinal Neoplasms; Neoplasm Metastasi

1963
CALCIUM AND PHOSPHATE METABOLISM IN PATIENTS WITH DISSEMINATED BREAST CANCER: EFFECT OF ANDROGENS AND OF PREDNISONE.
    The Journal of clinical endocrinology and metabolism, 1963, Volume: 23

    Topics: Androgens; Blood Chemical Analysis; Bone and Bones; Breast; Breast Neoplasms; Calcium; Calcium, Diet

1963
[CAVERN FORMATION IN LUNG METASTASES].
    Die Medizinische Welt, 1963, Dec-28, Volume: 52

    Topics: Caves; Cyclophosphamide; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Physiology; Prednisone

1963
TREATMENT OF INOPERABLE CARCINOMA WITH NEWER CHEMOTHERAPEUTIC AGENTS: REPORT OF THREE CASES.
    The Journal of the American Osteopathic Association, 1963, Volume: 63

    Topics: Bone Neoplasms; Breast Neoplasms; Humans; Methotrexate; Neoplasm Metastasis; Prednisone; Retroperito

1963
SOME UNUSUAL COMPLICATIONS OF METASTATIC CARCINOMA OF THE BREAST.
    Annals of surgery, 1964, Volume: 159

    Topics: Breast Neoplasms; Esophageal Diseases; Esophageal Neoplasms; Esophageal Stenosis; Gastrointestinal H

1964
NUTRITIONAL AND METABOLIC EFFECTS OF SOME NEWER STEROIDS. III. STANOZOLOL.
    New York state journal of medicine, 1964, Apr-01, Volume: 64

    Topics: Amputation, Surgical; Anabolic Agents; Blood Chemical Analysis; Dexamethasone; Diabetic Neuropathies

1964
PROPHYLACTIC ENDOCRINE TREATMENT IN CARCINOMA OF THE BREAST.
    Clinical radiology, 1964, Volume: 15

    Topics: Androgens; Breast Neoplasms; Castration; Cortisone; Estrogens; Female; Humans; Mastectomy; Menopause

1964
ENDOCRINE TREATMENT OF BREAST CANCER.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Anabolic Agents; Androgens; Breast Neoplasms; Castration; Estrone; Female; Humans; Menopause; Nandro

1964
NONSURGICAL TREATMENT OF PULMONARY CANCER.
    Modern treatment, 1964, Volume: 1

    Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen

1964
HEPATITIS AND--MALIGNANT NEOPLASIA.
    Medical times, 1964, Volume: 92

    Topics: Biopsy; Drug Therapy; Hepatic Encephalopathy; Hepatitis; Hepatitis A; Humans; Hydrocortisone; Hyperb

1964
SEVERE FLUSHING REACTIONS RESPONSIVE TO STEROIDS IN PATIENTS WITH BRONCHIAL CARCINOID.
    Lancet (London, England), 1964, Oct-10, Volume: 2, Issue:7363

    Topics: Bronchial Neoplasms; Chlorpromazine; Chromatography; Diagnosis, Differential; Humans; Hydroxyindolea

1964
REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU.
    New York state journal of medicine, 1964, Oct-01, Volume: 64

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; L

1964
HYPERCALCAEMIA IN RENAL CARCINOMA. REPORT OF A CASE.
    Acta medica Scandinavica, 1964, Volume: 176

    Topics: Alkaline Phosphatase; Blood; Bone Neoplasms; Calcium; Carcinoma; Carcinoma, Renal Cell; Electrocardi

1964
USE OF GLUCOCORTICOIDS IN THE PALLIATIVE TREATMENT OF METASTATIC BRAIN TUMORS.
    Cancer, 1965, Volume: 18

    Topics: Brain Neoplasms; Dexamethasone; Drug Therapy; Geriatrics; Glucocorticoids; Humans; Hydrocortisone; M

1965
CADAVERIC RENAL HOMOTRANSPLANTATION WITH INADVERTENT TRANSPLANTATION OF CARCINOMA.
    JAMA, 1965, May-31, Volume: 192

    Topics: Antineoplastic Agents; Azathioprine; Carcinoma, Bronchogenic; Drug Therapy; Humans; Immunosuppressiv

1965
HYPERCALCEMIA OF BREAST CANCER; MANAGEMENT WITH CORTICOSTEROIDS.
    Cancer, 1965, Volume: 18

    Topics: Adrenal Cortex Hormones; Breast Neoplasms; Calcium; Carcinoma; Drug Therapy; Geriatrics; Humans; Hyp

1965
MICROANGIOPATHIC HEMOLYTIC ANEMIA IN METASTATIC CARCINOMA. REPORT OF A CASE AND BIOCHEMICAL STUDIES.
    Archives of internal medicine, 1965, Volume: 116

    Topics: Anemia, Hemolytic; Bone Marrow Cells; Breast Neoplasms; Chemical Phenomena; Chemistry; Clinical Enzy

1965
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
    Aktuelle Urologie, 2005, Volume: 36, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antine

2005
Painful purpuric plaques on edematous hands.
    Archives of dermatology, 2005, Volume: 141, Issue:11

    Topics: Administration, Oral; Aged; Carcinosarcoma; Edema; Hand; Humans; Male; Neoplasm Metastasis; Pain; Pa

2005
Lessons to be learned: a case study approach. Lateral aberrant thyroid tissue: is it always malignant?
    The journal of the Royal Society for the Promotion of Health, 2007, Volume: 127, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor

2007
Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti

2007
The postchemotherapy PSA surge syndrome.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineo

2008
Intravascular coagulation, a possible accelerating effect of prednisone.
    Acta medica Scandinavica, 1966, Volume: 180, Issue:6

    Topics: Aged; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Platelets; Factor IX; Factor V;

1966
The electroencephalogram in hypercalcemia.
    Archives of neurology, 1967, Volume: 17, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Breast Neoplasms; Diethylstilbestrol; Electroencephalography; Est

1967
The endocrine aspects of trans-sphenoidal hypophysectomy.
    Canadian Medical Association journal, 1967, Jul-08, Volume: 97, Issue:2

    Topics: Adrenal Glands; Breast Neoplasms; Cortisone; Diabetes Mellitus; Diabetic Retinopathy; Female; Humans

1967
[Medical treatment of tumors].
    Minerva chirurgica, 1967, Jan-31, Volume: 22, Issue:2

    Topics: Antineoplastic Agents; Humans; Neoplasm Metastasis; Neoplasms; Prednisone

1967
Hormonal treatment of hypercalcemia caused by bone metastases.
    Canadian Medical Association journal, 1967, Sep-09, Volume: 97, Issue:11

    Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diethylstilbestrol; Female; Humans; Hypercalcemia; Middle Ag

1967
Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
    Cancer treatment reports, 1980, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C

1980
Steroid-withdrawal radiation pneumonitis in cancer patients.
    Chest, 1984, Volume: 85, Issue:6

    Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma, Small Cell; Combined Modality Therapy; Dexamethas

1984
[Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma].
    Onkologie, 1983, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S

1983
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
    Oncology, 1984, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmu

1984
Chemotherapy of advanced breast cancer. A general survey.
    Cancer, 1984, Feb-01, Volume: 53, Issue:3 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mo

1984
Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients.
    Cancer, 1984, Oct-01, Volume: 54, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Breast Neoplasms; Cy

1984
[Antibody-controlled cytostatic therapy of malignant thymoma with concomitant myasthenia gravis].
    Deutsche medizinische Wochenschrift (1946), 1984, Aug-17, Volume: 109, Issue:33

    Topics: Acetylcholine; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Cyclophosph

1984
Malignant thymoma with distant metastases: a case report and review of the literature.
    Japanese journal of clinical oncology, 1983, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; F

1983
Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
    Cancer, 1983, Jun-01, Volume: 51, Issue:11

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast

1983
[Combination chemotherapy for advanced diffuse non-Hodgkin's lymphomas in relapse following local radiotherapy].
    Rinsho hoshasen. Clinical radiography, 1983, Volume: 28, Issue:6

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo

1983
[Comparative evaluation of the results of mono- and polychemotherapy of disseminated forms of breast cancer using the CMFVP program and anthracycline antibiotics (carminomycin and adriamycin)].
    Antibiotiki, 1983, Volume: 28, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carubicin; Cyclophosphamide; Dauno

1983
Thymic rebound after treatment of childhood tumors.
    AJR. American journal of roentgenology, 1980, Volume: 135, Issue:1

    Topics: Child; Child, Preschool; Diagnosis, Differential; Female; Humans; Hypertrophy; Infant; Male; Mediast

1980
Near-haploid acute lymphoblastic leukemia: a unique subgroup with a poor prognosis?
    Blood, 1981, Volume: 58, Issue:1

    Topics: Acute Disease; Adolescent; Bone Marrow Examination; Brain Neoplasms; Child; Daunorubicin; Female; Ha

1981
Kaposi's sarcoma complicating corticosteroid therapy for temporal arteritis.
    The American journal of medicine, 1981, Volume: 71, Issue:2

    Topics: Aged; Female; Giant Cell Arteritis; Humans; Immunosuppression Therapy; Kidney Transplantation; Neopl

1981
A five-drug combination in the treatment of metastatic breast cancer.
    Cancer clinical trials, 1981, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female;

1981
[Results of, and indications for adjuvant chemotherapy in breast cancer].
    Schweizerische medizinische Wochenschrift, 1981, Jun-06, Volume: 111, Issue:23

    Topics: Adult; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans;

1981
Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations.
    European journal of cancer, 1980, Volume: Suppl 1

    Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F

1980
Combination chemotherapy in invasive thymoma role of COPP.
    Cancer, 1980, Oct-01, Volume: 46, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Co

1980
Modern approaches to the treatment of breast cancer.
    Blood, 1980, Volume: 56, Issue:5

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menstru

1980
Thymoma. A retrospective study of 87 cases.
    Cancer, 1994, May-15, Volume: 73, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C

1994
Should abdominal cluster transplantation be abandoned?
    Transplantation proceedings, 1993, Volume: 25, Issue:1 Pt 2

    Topics: Adult; Azathioprine; Child; Cyclosporine; Drug Therapy, Combination; Duodenum; Female; Gastrointesti

1993
Angiocentric T-cell lymphoma of the lung mimicking metastatic carcinoma. Case report.
    Journal of experimental & clinical cancer research : CR, 1998, Volume: 17, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic

1998
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2000, Volume: 6, Issue:4

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot

2000
Androgen-induced hepatoma.
    Lancet (London, England), 1975, Feb-22, Volume: 1, Issue:7904

    Topics: Adult; Anabolic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Cortisone; Cryptorchidism; Hemogl

1975
Esophageal carcinoma. The value of staging in long-term survival.
    The Annals of thoracic surgery, 1975, Volume: 19, Issue:6

    Topics: Administration, Oral; Cyclophosphamide; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Follo

1975
[Interstial pneumopathy after low dose bleomycin therapy].
    Schweizerische medizinische Wochenschrift, 1977, Oct-08, Volume: 107, Issue:40

    Topics: Bleomycin; Female; Hematopoiesis; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Pulmonary Fi

1977
A kinetically designed chemotherapeutic regimen for advanced refractory lymphoma patients.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:2

    Topics: Adolescent; Adult; Aged; Bleomycin; Doxorubicin; Drug Administration Schedule; Female; Hodgkin Disea

1978
[Chemotherapy of malignant skeletal tumors (author's transl)].
    Therapeutische Umschau. Revue therapeutique, 1979, Volume: 36, Issue:7

    Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Humans; Lymphoma; Melphalan; Multiple Myeloma; N

1979
Kappa light chain--myeloma associated with adult Fanconi syndrome: response of the nephropathy to treatment of myeloma.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:2

    Topics: Adult; Bence Jones Protein; beta 2-Microglobulin; Bone Neoplasms; Fanconi Syndrome; Female; Humans;

1978
Calcitonin treatment of hypercalcemia due to parathyroid carcinoma. Synergistic effect of prednisone on long-term treatment of hypercalcemia.
    Archives of internal medicine, 1975, Volume: 135, Issue:12

    Topics: Adult; Bone Resorption; Calcitonin; Calcium; Drug Synergism; Humans; Hypercalcemia; Male; Neoplasm M

1975
[Confluent pulmonary deposits from carcinoma of the breast under cytostatic therapy (author's transl)].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1976, Volume: 125, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Female; H

1976
Leukemia in children with Wilms tumor.
    The Journal of pediatrics, 1975, Volume: 87, Issue:3

    Topics: Acute Disease; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans

1975
Neoplasia in kidney transplant recipients.
    American journal of surgery, 1975, Volume: 130, Issue:5

    Topics: Adult; Azathioprine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Huma

1975
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
    Medizinische Klinik, 1976, Oct-01, Volume: 71, Issue:40

    Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car

1976
Leucovorin in combination chemotherapy of breast cancer.
    Clinical pharmacology and therapeutics, 1977, Volume: 21, Issue:4

    Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Le

1977
Current treatment of acute leukemia.
    Comprehensive therapy, 1978, Volume: 4, Issue:2

    Topics: Bone Marrow Transplantation; Child; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Lymphoid; Le

1978
"Disappearing" spinal cord compression: oncolytic effect of glucocorticoids (and other chemotherapeutic agents) on epidural metastases.
    Annals of neurology, 1977, Volume: 2, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dexamethasone; Dysgerminoma; Epidural Space; Humans;

1977
Chemotherapy for breast cancer.
    Comprehensive therapy, 1979, Volume: 5, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F

1979
[The period of time between operation and irradiation of a mamma carcinoma and its cytostatic treatment (author's transl)].
    Strahlentherapie, 1979, Volume: 155, Issue:3

    Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis;

1979
Treatment and survival in advanced breast cancer.
    British medical journal, 1979, Feb-24, Volume: 1, Issue:6162

    Topics: Breast Neoplasms; Estradiol Congeners; Female; Humans; Neoplasm Metastasis; Prednisone; Research Des

1979
Adrenocortical carcinoma in a patient with systemic lupus erythematosus treated with azathioprine.
    Arthritis and rheumatism, 1979, Volume: 22, Issue:8

    Topics: Adrenal Cortex Neoplasms; Azathioprine; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Ne

1979
[Extraskeletal manifestations of unusual localization in a case of myeloma (author's transl)].
    Medicina clinica, 1979, Jul-15, Volume: 73, Issue:3

    Topics: Female; Humans; Immunoglobulin G; Lymphatic Metastasis; Melphalan; Middle Aged; Multiple Myeloma; Ne

1979
Potentiating role of previously administered agents in the combination chemotherapy of breast cancer.
    Oncology, 1979, Volume: 36, Issue:4

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Drug Therapy, Comb

1979
[Association of VCR-5FU-CYCLO-PDN in the treatment of disseminated carcinoma of the breast (author's transl)].
    Medicina clinica, 1979, Aug-15, Volume: 73, Issue:4

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Evaluation Studies a

1979
Sequence for developing optimal combination chemotherapy of metastatic breast cancer.
    European journal of cancer, 1979, Volume: 15, Issue:10

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr

1979
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
    Urology, 1978, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hu

1978
Chemotherapy of solid tumors.
    The Medical journal of Australia, 1978, Mar-25, Volume: 1, Issue:6

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Drug Therapy, Combination; Humans; Male; Neoplasm Metas

1978
Clinical trial of nafoxidine in advanced breast cancer.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:2

    Topics: Adult; Aged; Breast Neoplasms; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Mid

1978
Treatment of hepatic metastases from breast cancer.
    Clinical oncology, 1978, Volume: 4, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F

1978
Regression of malignant thymoma with metastases after treatment with adrenocortical steroids.
    Israel journal of medical sciences, 1978, Volume: 14, Issue:4

    Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Thymoma; Thymus Neoplasms

1978
Invasive thymoma responsive to oral corticosteroids.
    Cancer treatment reports, 1978, Volume: 62, Issue:9

    Topics: Administration, Oral; Humans; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Pleural

1978
Complete maturation of neuroblastoma with bone metastases in documented stages.
    Journal of pediatric surgery, 1975, Volume: 10, Issue:4

    Topics: Bone Neoplasms; Child, Preschool; Cyclophosphamide; Female; Ganglioneuroma; Humans; Infant; Mercapto

1975
Systemic therapy for metastatic breast cancer.
    Annals of internal medicine, 1977, Volume: 86, Issue:1

    Topics: BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Estrogens; Female; Fluor

1977
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
    The Journal of urology, 1977, Volume: 117, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug The

1977
Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combinatio

1977
Initial relapses in previously treated Hodgkin's disease. I. Results of second treatment.
    Cancer, 1976, Volume: 37, Issue:6

    Topics: Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Neoplasm Metastasis; Neoplasm Recurrence, Lo

1976
[Preliminary experiences in the treatment of metastatic mamma carcinoma by polychemotherapy-according to Cooper (author's transl)].
    Radiobiologia, radiotherapia, 1976, Volume: 17, Issue:3

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Combinations; Drug Therapy, Combination; Female; Fluorourac

1976
Combination chemotherapy in the treatment of advanced breast cancer.
    Journal of surgical oncology, 1976, Volume: 8, Issue:6

    Topics: Adrenalectomy; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Co

1976
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
    Urology, 1976, Volume: 8, Issue:6

    Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil;

1976
[Primary (?) retroperitoneal seminoma with multiple metastases and elevated serum alkaline phosphatase (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1976, Dec-07, Volume: 65, Issue:49

    Topics: Adrenal Gland Neoplasms; Alkaline Phosphatase; Cyclophosphamide; Dysgerminoma; Humans; Male; Middle

1976
Generalized osteoblastic bony metastases from medulloblastoma.
    Oncology, 1976, Volume: 33, Issue:5-6

    Topics: Adult; Bone Neoplasms; Brain Neoplasms; Cyclophosphamide; Humans; Male; Medulloblastoma; Neoplasm Me

1976
Combination chemotherapy for disseminated carcinoma of the breast.
    Boletin de la Asociacion Medica de Puerto Rico, 1975, Volume: 67, Issue:6

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Com

1975
Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone.
    Cancer, 1976, Volume: 38, Issue:2

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; F

1976
Chemotherapy of breast cancer.
    Connecticut medicine, 1975, Volume: 39, Issue:1

    Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu

1975
Hyperlucent lung after radiation therapy.
    The American review of respiratory disease, 1975, Volume: 112, Issue:2

    Topics: Angiography; Bone Neoplasms; Breast Neoplasms; Chlorambucil; Dyspnea, Paroxysmal; Female; Humans; Lu

1975
Chemotherapy in the treatment strategy of breast cancer.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu

1975
Infiltrative retinopathy in systemic lymphoma.
    American journal of ophthalmology, 1975, Volume: 79, Issue:1

    Topics: Cobalt; Cyclophosphamide; Eye Neoplasms; Female; Fluorescein Angiography; Fundus Oculi; Humans; Ison

1975
Lymphosarcoma of the right atrium. Angiographic and hemodynamic documentation of response to chemotherapy.
    Archives of internal medicine, 1975, Volume: 135, Issue:2

    Topics: Adult; Angiocardiography; Cardiac Catheterization; Coronary Circulation; Heart Atria; Heart Neoplasm

1975
A controlled study in the use of combined drug therapy for metastatic breast cancer.
    Cancer, 1975, Volume: 36, Issue:4

    Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Drug Therapy,

1975
Non-Hodgkin's lymphoma in children.
    Medical and pediatric oncology, 1975, Volume: 1, Issue:3

    Topics: Adolescent; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Child; Child, Preschool; Cycloph

1975
Editorial: Major advance in breast-cancer therapy.
    The New England journal of medicine, 1976, Feb-19, Volume: 294, Issue:8

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil

1976
Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy.
    Cancer, 1976, Volume: 37, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Asparaginase; Carmustine; Child; Child, Preschool; Cyclophosphami

1976
Combination chemotherapy for advanced breast cancer: response and effect on survival.
    Annals of internal medicine, 1976, Volume: 84, Issue:4

    Topics: Adult; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Li

1976
Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution?
    European journal of haematology, 1992, Volume: 49, Issue:2

    Topics: Cytokines; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Melphalan; Middle

1992
The effect of corticosteroid administration on bleomycin lung toxicity.
    Cancer, 1990, Mar-15, Volume: 65, Issue:6

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin;

1990
Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
    Cancer, 1990, Jun-01, Volume: 65, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Evaluation;

1990
Short term high density systemic therapy for metastatic breast cancer.
    Breast cancer research and treatment, 1985, Volume: 5, Issue:2

    Topics: Altretamine; Antineoplastic Agents; Bleomycin; Breast Neoplasms; Combined Modality Therapy; Doxorubi

1985
[Treatment of metastatic breast cancer].
    Harefuah, 1986, Volume: 111, Issue:1-2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacar

1986
[Radiotherapy with neoadjuvant chemotherapy].
    Annales de medecine interne, 1989, Volume: 140, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorub

1989
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:5

    Topics: Aged; Analgesics; Androgens; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Prednisone; Prosp

1989
[The effect of chemotherapy on survival time in advanced breast carcinoma].
    Deutsche medizinische Wochenschrift (1946), 1989, Jun-16, Volume: 114, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo

1989
Disseminated thymoma and myasthenia gravis: dramatic response to prednisone.
    Annals of neurology, 1989, Volume: 25, Issue:2

    Topics: Combined Modality Therapy; Female; Humans; Middle Aged; Myasthenia Gravis; Neoplasm Metastasis; Pred

1989
Effect of initial resection of small-cell carcinoma of the lung: a review of Southwest Oncology Group Study 7628.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Small Cell; Combined Modalit

1985
Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
    Cancer treatment reports, 1987, Volume: 71, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Flu

1987
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.
    Wiener klinische Wochenschrift, 1986, Dec-05, Volume: 98, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour

1986
De-novo brain tumours in renal-transplant recipients.
    Lancet (London, England), 1971, May-15, Volume: 1, Issue:7707

    Topics: Adolescent; Adult; Azathioprine; Brain; Brain Neoplasms; Cadaver; Follow-Up Studies; Humans; Immunos

1971
Current concepts in the treatment of advanced breast cancer.
    Oncology, 1972, Volume: 26, Issue:2

    Topics: Adrenalectomy; Adult; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Fluorouracil; Huma

1972
Hemangiosarcoma and pathologic rupture of the spleen.
    Cancer, 1973, Volume: 31, Issue:5

    Topics: Bleomycin; Female; Hemangiosarcoma; Humans; Middle Aged; Neoplasm Metastasis; Prednisone; Splenectom

1973
Palliative treatment of mammary cancer. Response of soft tissue, pleural and pulmonary disease.
    Archives of surgery (Chicago, Ill. : 1960), 1973, Volume: 107, Issue:1

    Topics: Adrenalectomy; Adult; Age Factors; Aged; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethaso

1973
Association of malignant melanoma and malignant lymphoma.
    Lancet (London, England), 1973, Aug-04, Volume: 2, Issue:7823

    Topics: Biopsy; Cyclophosphamide; Lymphatic Metastasis; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasm Re

1973
The treatment of pulmonary metastases of malignant teratoma of the testis.
    Clinical radiology, 1973, Volume: 24, Issue:1

    Topics: Chlorambucil; Dactinomycin; Humans; Lung Neoplasms; Male; Methotrexate; Neoplasm Metastasis; Pneumon

1973
Rapid fractionation technique and re-treatment of cerebral metastases by irradiation.
    Cancer, 1974, Volume: 34, Issue:2

    Topics: Brain Neoplasms; Dexamethasone; Female; Humans; Male; Neoplasm Metastasis; Palliative Care; Predniso

1974
Florid keratoacanthomas in a kidney transplant recipient. Case report.
    Scandinavian journal of plastic and reconstructive surgery, 1974, Volume: 8, Issue:3

    Topics: Azathioprine; Carcinoma, Squamous Cell; Dactinomycin; Graft Rejection; Humans; Immunosuppression The

1974
Management of far-advanced carcinoma of the lung.
    Geriatrics, 1966, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alkylating Agents; Brain Neoplasms; Carcinoma; Carcin

1966
Spontaneous rupture of the spleen on plasma cell leukemia.
    Canadian Medical Association journal, 1969, Jan-04, Volume: 100, Issue:1

    Topics: Bence Jones Protein; Blood Protein Electrophoresis; Bone Marrow Examination; Diagnosis, Differential

1969
Dermatofibrosarcoma protuberans with metastases treated with methotrexate.
    American journal of surgery, 1970, Volume: 120, Issue:1

    Topics: Chemotherapy, Cancer, Regional Perfusion; Chin; Facial Neoplasms; Fibrosarcoma; Humans; Male; Methot

1970
Disseminated toxoplasmosis in the compromised host. A report of five cases.
    Archives of internal medicine, 1974, Volume: 134, Issue:6

    Topics: Adult; Aged; Anemia, Hemolytic, Autoimmune; Autopsy; Azathioprine; Brain; Breast Neoplasms; Female;

1974
Hypercalcemia associated with chronic lymphocytic leukemia. Treatment with mithramycin.
    Postgraduate medicine, 1973, Volume: 53, Issue:7

    Topics: Bone Neoplasms; Diuretics; Humans; Hypercalcemia; Kidney; Leukemia, Lymphoid; Lung; Lymphoma, Non-Ho

1973
Hypercalcemia complicating breast cancer. Clinical features and management.
    Oncology, 1973, Volume: 28, Issue:2

    Topics: Adrenalectomy; Bone Neoplasms; Breast Neoplasms; Diet Therapy; Female; Humans; Hydrocortisone; Hyper

1973
Chemotherapy in the treatment of leukemia and Wilms' tumor.
    JAMA, 1966, Nov-21, Volume: 198, Issue:8

    Topics: Aminopterin; Antineoplastic Agents; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Leuk

1966
Islet cell tumor of the pancreas with reversible watery diarrhea and achylorhydraia.
    Gastroenterology, 1967, Volume: 52, Issue:4

    Topics: Achlorhydria; Adenoma, Islet Cell; Adult; Diarrhea; Gastric Acidity Determination; Gastric Juice; Hu

1967
Insulin-secreting bronchial carcinoid tumor with widespread metastases.
    The American journal of medicine, 1968, Volume: 44, Issue:4

    Topics: Adult; Blood Glucose; Bronchi; Bronchial Neoplasms; Carcinoma, Adenoid Cystic; Diazoxide; Female; Gl

1968
Control of hypoglycemia with diazoxide and hormones.
    Annals of the New York Academy of Sciences, 1968, Apr-11, Volume: 150, Issue:2

    Topics: Adenoma, Islet Cell; Adrenocorticotropic Hormone; Aged; Benzothiadiazines; Blood Glucose; Diazoxide;

1968
Clinical and pathologic observations after orthotopic transplantation of the human liver.
    Surgery, gynecology & obstetrics, 1969, Volume: 128, Issue:2

    Topics: Adolescent; Adult; Alkaline Phosphatase; Azathioprine; Bilirubin; Blood Proteins; Carcinoma, Hepatoc

1969
[Therapeutic possibilities in metastatic cancer of the breast with hypercalcaemia. (Apropos of 2 cases)].
    Revue du rhumatisme et des maladies osteo-articulaires, 1969, Volume: 36, Issue:11

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Bone Neoplasms; Breast Neoplasms; Castration; Cyc

1969
[Bronchial carcinoid. Apropos of 5 cases, one of which was a carcinoid syndrome].
    Acta chirurgica Belgica, 1969, Volume: 68, Issue:4

    Topics: Adenoma; Adult; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; Carcinoma, Adenoi

1969
Personal experience with orthotopic liver transplantation.
    Transplantation proceedings, 1972, Volume: 4, Issue:4

    Topics: Adolescent; Antilymphocyte Serum; Biliary Tract Diseases; Bilirubin; Carcinoma, Hepatocellular; Chil

1972
Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone.
    Archives of internal medicine, 1973, Volume: 132, Issue:5

    Topics: Adolescent; Adult; Arginine; Blood; Carcinoma, Small Cell; Cyclophosphamide; Humans; Leukemia, Lymph

1973
Diazoxide, encorton and streptozotocin in the treatment of malignant betacytoma.
    Acta medica Polona, 1974, Volume: 15, Issue:1

    Topics: Adenoma, Islet Cell; Adult; Autopsy; Diazoxide; Female; Glucose; Humans; Hypoglycemia; Liver Neoplas

1974
Malignant lymphoma invading the facial nerve.
    Archives of otolaryngology (Chicago, Ill. : 1960), 1974, Volume: 99, Issue:6

    Topics: Child; Cochlear Nerve; Colon; Electric Stimulation; Facial Nerve; Facial Paralysis; Female; Humans;

1974
[Diagnostic problems raised by tumors of the skull. A propos 2 cases (author's transl)].
    Acta chirurgica Belgica, 1974, Volume: 73, Issue:5

    Topics: Aged; Biopsy; Cyclophosphamide; Diagnosis, Differential; Frontal Bone; Humans; Immunoelectrophoresis

1974
[Hormone therapy and chemotherapy of metastasizing breast cancer. Experiences of the Basle Oncology Center, 1969-72].
    Schweizerische medizinische Wochenschrift, 1974, Aug-03, Volume: 104, Issue:31

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Castration; Cyclophosphamide; Drug Therapy, Comb

1974
Hormonal therapy in metastatic hypernephroma.
    Urology, 1974, Volume: 4, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Male;

1974
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)].
    La Nouvelle presse medicale, 1972, Jun-24, Volume: 1, Issue:26

    Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; D

1972
[1st experiences with Adriamycin, a new cytotoxic antibiotic, in combination chemotherapy of malignant tumors].
    Schweizerische medizinische Wochenschrift, 1972, Aug-26, Volume: 102, Issue:34

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma; Drug Synergism; F

1972
Acute leukemia complicating metastatic breast cancer.
    Cancer, 1973, Volume: 31, Issue:3

    Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil

1973
Combination chemotherapy in disseminated carcinoma of the breast.
    Oncology, 1974, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Stu

1974
Blood and neoplastic diseases. Acute lymphoblastic leukaemia.
    British medical journal, 1974, Nov-02, Volume: 4, Issue:5939

    Topics: Arachnoid; Asparaginase; Brain Neoplasms; Cerebrospinal Fluid; Child; Cyclophosphamide; Daunorubicin

1974
Liver transplantation: a clinical and immunological appraisal.
    Progress in liver diseases, 1972, Volume: 4

    Topics: Adult; Animals; Autoantibodies; Azathioprine; Biliary Fistula; Cell Migration Inhibition; Complement

1972
Eight- to ten-year follow-up in early cases of renal homotransplantation.
    Transplantation proceedings, 1973, Volume: 5, Issue:1

    Topics: Adolescent; Adult; Azathioprine; Blood Group Incompatibility; Carcinoma, Basal Cell; Carcinoma, Baso

1973
Blood and neoplastic diseases. Treatment of the lymphomas.
    British medical journal, 1974, Dec-28, Volume: 4, Issue:5947

    Topics: Alopecia; Bone Marrow; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Ne

1974
[Theory and practice of systemic cancer therapy].
    Wiener medizinische Wochenschrift (1946), 1972, Nov-18, Volume: 122, Issue:47

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cyclophosphamide; Family Practice; Female; H

1972
Five-drug combination chemotherapy for disseminated adenocarcinoma.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:6

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug

1972
[Treatment of Hodgkin's disease of the stomach].
    Deutsche medizinische Wochenschrift (1946), 1973, Jan-26, Volume: 98, Issue:4

    Topics: Adult; Cyclophosphamide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Metastasis; Pr

1973
[On the use of isotope hypophysectomy with yttrium 90 in mammary neoplasms].
    Studii si cercetari de endocrinologie, 1973, Volume: 24, Issue:2

    Topics: Breast Neoplasms; Cortisone; Humans; Mastectomy; Neoplasm Metastasis; Pituitary Irradiation; Postope

1973
Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.
    Canadian Medical Association journal, 1973, Mar-17, Volume: 108, Issue:6

    Topics: Adenocarcinoma; Adrenalectomy; Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Huma

1973
Secondary chemotherapy of advanced breast cancer.
    Cancer, 1973, Volume: 31, Issue:3

    Topics: Adult; Aged; Breast Neoplasms; Chlorambucil; Female; Humans; Hydrocortisone; Middle Aged; Neoplasm M

1973
[Iatrogenic diabetic coma. Contribution to adverse effects of cytostatic therapy].
    Strahlentherapie, 1973, Volume: 145, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Diabetic Coma; Female; Fluorouracil; Huma

1973
[Significance of ( 85 Sr) radioisotope bone scanning in the early diagnosis of bone metastases and possibilities of their therapy].
    Zeitschrift fur arztliche Fortbildung, 1973, Feb-15, Volume: 67, Issue:4

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Castration; Cobalt Isotopes; Female;

1973
Extra-axial spread of medulloblastoma.
    Cancer, 1973, Volume: 31, Issue:5

    Topics: Autopsy; Brain Neoplasms; Carmustine; Cranial Fossa, Posterior; Femoral Neoplasms; Humans; Liver Neo

1973
Combination chemotherapy in disseminated carcinoma of the breast.
    Surgery, gynecology & obstetrics, 1973, Volume: 137, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Humans; Metho

1973
Thrombocytopenia from metastatic carcinoma of the breast. Effective managements of patients with this complication.
    Archives of surgery (Chicago, Ill. : 1960), 1973, Volume: 107, Issue:4

    Topics: Adrenalectomy; Aged; Blood Cell Count; Blood Platelets; Bone Marrow; Bone Neoplasms; Breast Neoplasm

1973
Disseminated breast carcinoma. Treatment with combination chemotherapy.
    Archives of internal medicine, 1973, Volume: 132, Issue:4

    Topics: Adenocarcinoma; Adult; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fem

1973
[Cytostatic combination therapy in metastatic breast cancer].
    Ugeskrift for laeger, 1973, Jun-18, Volume: 135, Issue:25

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F

1973
Childhood leukaemia presenting in the central nervous system.
    Archives of disease in childhood, 1973, Volume: 48, Issue:11

    Topics: Autopsy; Brain Neoplasms; Child; Child, Preschool; Daunorubicin; Humans; Leukemia; Male; Mercaptopur

1973
[Cooper's combination chemotherapy of metastasizing breast carcinoms].
    Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1973, Volume: 79

    Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Methotrexate; Middle

1973
An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.
    Surgery, gynecology & obstetrics, 1974, Volume: 138, Issue:1

    Topics: Administration, Oral; Adult; Aged; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Drug Therap

1974
Cyclical combination chemotherapy for advanced breast carcinoma.
    British medical journal, 1974, Feb-09, Volume: 1, Issue:5901

    Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos

1974
[Carcinoma of the male breast].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1974, Jan-10, Volume: 94, Issue:1

    Topics: Breast Neoplasms; Carcinoma; False Negative Reactions; Humans; Male; Mastectomy; Middle Aged; Neopla

1974
Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress.
    Cancer, 1974, Volume: 33, Issue:5

    Topics: Adrenalectomy; Adult; Aged; Breast Neoplasms; Carcinoembryonic Antigen; Castration; Cyclophosphamide

1974
Testicular involvement in plasma-cell leukemia.
    Urology, 1974, Volume: 3, Issue:5

    Topics: Allopurinol; Cyclophosphamide; Humans; Leukemia, Plasma Cell; Male; Middle Aged; Multiple Myeloma; N

1974
[Letter: Prednisone treatment of breast cancer with metastases].
    Ugeskrift for laeger, 1974, Jun-10, Volume: 136, Issue:24

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Carcinoma; Female; Femoral Neoplasms; Humans; Neoplas

1974
Azathioprine for pemphigus and pemphigoid--a 4 year follow-up.
    The British journal of dermatology, 1974, Volume: 91, Issue:1

    Topics: Adult; Aged; Anemia; Azathioprine; Bone Neoplasms; Drug Evaluation; Drug Hypersensitivity; Female; F

1974
Leiomyosarcoma in a renal allograft recipient treated with immunosuppressive drugs.
    JAMA, 1971, Mar-29, Volume: 215, Issue:13

    Topics: Adenocarcinoma; Adult; Age Factors; Autopsy; Azathioprine; Histocompatibility; Humans; Immunosuppres

1971
Apparent chemotherapeutic cure of malignant lymphoma.
    Cancer, 1971, Volume: 27, Issue:4

    Topics: Adult; Antineoplastic Agents; Cyclophosphamide; Diagnosis, Differential; Histological Techniques; Hu

1971
Combined chemotherapy and radiotherapy for advanced Hodgkin's disease and reticulum cell sarcoma: a preliminary report.
    Southern medical journal, 1971, Volume: 64, Issue:7

    Topics: Adolescent; Adult; Aged; Blood Cell Count; Cyclophosphamide; Female; Hodgkin Disease; Humans; Lympho

1971
Hemodynamic studies in two long-term survivors of heart transplantation.
    The Journal of thoracic and cardiovascular surgery, 1971, Volume: 62, Issue:2

    Topics: Adult; Angiography; Antilymphocyte Serum; Aorta; Autopsy; Azathioprine; Blood Pressure; Cardiac Cath

1971
Malignant lymphomas in transplantation patients.
    Transplantation proceedings, 1969, Volume: 1, Issue:1

    Topics: Adolescent; Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Humans; Immunosuppre

1969
Carcinoma of the testis in a renal transplant recipient.
    The American journal of the medical sciences, 1971, Volume: 262, Issue:3

    Topics: Adult; Azathioprine; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Kidney Trans

1971
Fluoride therapy for pain in malignant bone disease.
    Radiology, 1968, Volume: 90, Issue:3

    Topics: Adult; Aged; Analgesia; Bone Neoplasms; Breast Neoplasms; Estrogens; Fluorides; Fluoxymesterone; Hum

1968
[The practitioner's approach to acute hypercalcemia].
    La Presse medicale, 1969, Jun-21, Volume: 77, Issue:30

    Topics: Acute Disease; Animals; Bone Neoplasms; Calcitonin; Diet Therapy; Edetic Acid; Humans; Hypercalcemia

1969
Acute leukemia terminating in histiocytic medullary reticulosis.
    Archives of pathology, 1972, Volume: 93, Issue:3

    Topics: Adolescent; Autopsy; Bone Marrow Examination; Erythrocytes; Histiocytes; Humans; Kidney; Leukemia, L

1972
Pseudohyperparathyroidism and seminoma.
    The Journal of urology, 1972, Volume: 107, Issue:5

    Topics: Acute Disease; Adult; Blood Urea Nitrogen; Calcium; Diagnosis, Differential; Dysgerminoma; Humans; H

1972
The phase II study: some reflections, particularly concerning disseminated breast cancer.
    Cancer chemotherapy reports. Part 3, 1972, Volume: 3, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclohexanes; Cyclophosphamide; Female; Fluorou

1972
Chemotherapy in the management of metastatic cancer of unknown primary site.
    Oncology, 1972, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho

1972
Chemotherapy of breast carcinoma.
    Oncology, 1972, Volume: 26, Issue:2

    Topics: Adult; Amines; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; Humans; Imida

1972
An evaluation of the management of patients with cerebral metastases from malignant melanoma.
    Cancer, 1972, Volume: 29, Issue:3

    Topics: Adult; Aged; Amides; Brain; Brain Neoplasms; Coma; Dexamethasone; Evaluation Studies as Topic; Femal

1972
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.
    The New England journal of medicine, 1972, Nov-30, Volume: 287, Issue:22

    Topics: Adolescent; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Drug-Related S

1972
Bone collagen and calcium metabolism in normocalcemic and hypercalcemic patients with breast cancer.
    Cancer, 1971, Volume: 27, Issue:5

    Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Calcium; Collagen; Co

1971
[Case of thyroid lymphosarcoma].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1971, Feb-15, Volume: 24, Issue:4

    Topics: Aged; Female; Humans; Lymphoma, Non-Hodgkin; Neoplasm Metastasis; Prednisone; Radiography, Thoracic;

1971
[Studies on calcium metabolism in humans with the aid of a whole body counter. Whole body retention of Ca47 in the healthy and in patients with tumors and other diseases].
    Radiologia clinica et biologica, 1971, Volume: 40, Issue:3

    Topics: Adult; Age Factors; Aged; Bone Diseases; Bone Neoplasms; Calcium; Calcium Isotopes; Cortisone; Femal

1971
Five-drug therapy for advanced breast cancer: a phase I study.
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans

1971
[Hemangiopericytoma with metastases. Effect of prednisone treatment].
    Pediatrie, 1971, Volume: 26, Issue:8

    Topics: Brain Diseases; Buttocks; Child, Preschool; Cysts; Hemangiopericytoma; Humans; Infant; Infant, Newbo

1971
Autoimmune hemolytic anemia and ulcerative colitis: a multisystem immunodeficiency disease?
    International archives of allergy and applied immunology, 1970, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Anti-Idiotypic; Blood Cell Count; Bloo

1970
A simultaneous modification of A agglutinogen of erythrocytes and loss of specific platelet antigens in a patient with gall bladder carcinoma.
    Neoplasma, 1969, Volume: 16, Issue:3

    Topics: Agglutination Tests; Antigens; Blood Group Antigens; Blood Platelets; Erythrocytes; Female; Gallblad

1969
Evaluation of adrenalectomy and hypophysectomy in the treatment of metastatic cancer of the breast.
    Cancer, 1969, Volume: 24, Issue:6

    Topics: Adrenalectomy; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypophysectomy; Ne

1969
Bone marrow metastases in children with solid tumors.
    American journal of diseases of children (1960), 1970, Volume: 119, Issue:1

    Topics: Bone Marrow Diseases; Bone Marrow Examination; Bone Neoplasms; Child; Cyclophosphamide; Dactinomycin

1970
Combined chemotherapy of epithelial tumours.
    Neoplasma, 1970, Volume: 17, Issue:3

    Topics: Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Dactinomycin; DNA, Neoplasm; Female; Humans; Ma

1970
[Clinical aspects of malignant pleurisy].
    Radiologia diagnostica, 1970, Volume: 11, Issue:5

    Topics: Adult; Aged; Biopsy; Diagnosis, Differential; Female; Humans; Male; Mesothelioma; Middle Aged; Neopl

1970
[Hypercalcemia syndrome in bronchial carcinoma without skeletal metastasizing].
    Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1970, Sep-15, Volume: 25, Issue:18

    Topics: Bronchial Neoplasms; Carcinoma, Squamous Cell; Cardiac Glycosides; Female; Humans; Hypercalcemia; Hy

1970
Retroperitoneal malignant mesenchymoma.
    The Journal of urology, 1971, Volume: 106, Issue:1

    Topics: Adult; Aortography; Child, Preschool; Cyclophosphamide; Dactinomycin; Female; Humans; Male; Melphala

1971
Hormonal therapy in advanced renal cell carcinoma.
    Cancer, 1971, Volume: 28, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Brain Neoplasms; Female; Humans; Hydroxyprogesterones;

1971
Bilateral inflammatory pseudotumors of the ciliary body.
    American journal of ophthalmology, 1971, Volume: 72, Issue:3

    Topics: Administration, Topical; Anti-Inflammatory Agents; Atropine; Biopsy; Ciliary Body; Diagnosis, Differ

1971
Treatment of advanced cancer of the breast with 5-fluorouracil.
    The American surgeon, 1971, Volume: 37, Issue:5

    Topics: Adult; Aged; Breast Neoplasms; Castration; Cobalt Isotopes; Female; Fluorouracil; Humans; Mastectomy

1971
Malignancy during methotrexate and steroid therapy for psoriasis.
    Archives of dermatology, 1971, Volume: 103, Issue:5

    Topics: Adult; Carcinoma, Squamous Cell; Humans; Immunosuppression Therapy; Lung Neoplasms; Male; Methotrexa

1971
[The present position of hormone treatment of metastasizing cancer diseases].
    Praxis, 1967, Nov-30, Volume: 56, Issue:48

    Topics: Breast Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Male; Neoplasm Metastasis; Pr

1967
Hypercalcemia accompanying ovarian mesonephroma without skeletal metastasis.
    Southern medical journal, 1968, Volume: 61, Issue:4

    Topics: Alkaline Phosphatase; Calcium; Electroencephalography; Female; Humans; Hydrocortisone; Hypercalcemia

1968
A radioisotopic method for determining optimum non-surgical therapy for advanced cancer. II. Clinical experience.
    Annals of surgery, 1968, Volume: 168, Issue:3

    Topics: Adenocarcinoma; Breast Neoplasms; Diethylstilbestrol; Female; Fluorouracil; Fluoxymesterone; Gastroi

1968
Effect of artificially induced abacterial erysipelas and of chronic aseptic abscess on human and experimental neoplasms.
    Polish medical journal, 1968, Volume: 7, Issue:5

    Topics: Abscess; Adult; Aged; Amylases; Anemia; Animals; Breast Neoplasms; Child; Erysipelas; Eye Neoplasms;

1968
Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy.
    Cancer chemotherapy reports, 1968, Volume: 52, Issue:7

    Topics: Breast Neoplasms; Cyclophosphamide; Diethylstilbestrol; Female; Fluorouracil; Humans; Neoplasm Metas

1968
Metastatic carcinoma to the choroid with choroidal detachment. A case presenting as uveal effusion.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1969, Volume: 82, Issue:2

    Topics: Carcinoma; Choroid; Choroid Neoplasms; Eye Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neop

1969
[Possibilities of treatment of meningeal dissemination in leukemia and malignant tumors in adults].
    Schweizerische medizinische Wochenschrift, 1969, Mar-08, Volume: 99, Issue:10

    Topics: Adult; Brain Neoplasms; Female; Humans; Injections, Spinal; Intracranial Pressure; Leukemia; Male; M

1969
Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors.
    The American journal of medicine, 1965, Volume: 39, Issue:4

    Topics: Adenoma; Adult; Aortic Valve Stenosis; Bronchial Neoplasms; Carcinoid Tumor; Electrocardiography; Fe

1965
Hormone therapy in metastatic breast cancer: clinical response and urinary gonadotrophins.
    Acta endocrinologica, 1965, Volume: 50, Issue:3

    Topics: Aged; Anabolic Agents; Breast Neoplasms; Diethylstilbestrol; Female; Gonadotropins; Humans; Neoplasm

1965
Hypercalcemia in patients with advanced mammary cancer and osseous metastases. Effect of hormone therapy and schedule of treatment.
    The American surgeon, 1966, Volume: 32, Issue:10

    Topics: Adult; Bone Neoplasms; Breast Neoplasms; Calcium; Estradiol; Female; Humans; Hypercalcemia; Middle A

1966
[A previously unknown mechanism of the development of hypercalcemias in leukemia].
    Deutsche medizinische Wochenschrift (1946), 1966, Dec-02, Volume: 91, Issue:48

    Topics: Aged; Calcium; Female; Humans; Hypercalcemia; Hyperparathyroidism; Leukemia; Neoplasm Metastasis; Pa

1966
[Conservative hormonal treatment of metastatic mammary cancer].
    Neuro-Chirurgie, 1966, Volume: 12, Issue:6

    Topics: Breast Neoplasms; Estrogens; Female; Humans; Nandrolone; Neoplasm Metastasis; Ovary; Prednisone; Rad

1966